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In this study I explored the possibility of making HIV -1 subtype C PrSSgag-based chimaeric virus-
like particles (VLPs) as a boost to the HIV-IC multigene DNA vaccine pTHr.grttnC, which 
encodes a modified Gag-RT-Tat-Nef fusion protein (GRTTN). Furthennore, an attempt was 
made to produce VLP analogues to the HIV-IA polyepitope DNA vaccinc pTHr.HIVA. A range 
of in-frame fusions with the C-tennini of myristylation-competent p6-truncated Gag and native 
Pr5S gag were made to test how the length of polypeptide and its sequence might affect VLP 
fonnation and structure. The fused peptides included an artificial HIV -1 A pol yepitope string 
(PE, 155 aa); the truncated protein sequences 3RT (113 aa) and 3 'TN (169 aa), and the entire RT 
(450 aa) and TN (322 aa) and RTTN portions (778 aa) of GRTTN. Baculovirus-expressed 
chimaeric proteins were examined by western blot and electron microscopy. Pr55gag without a 
myristylation signal was localized to the insect cell nucleus where aggregations of multilayered 
Gag structures were observed. Removal of p6 in addition to the myristylation signal resulted in 
only partial nuclear localization with individual Gag structures also present in the cytoplasm. All 
Gag chimaeras, except for the Gag-PE fusions, localized to the cell membrane and fonned 
regular budded structures that could be purified from the culture medium. Particle diameter 
increased with protein molecular weight, from -100 nm for native PrSSgag to -250 nm for 
Gag-RTTN fusions. The presence or absence of the Gag p6 region did not obviously affect VLP 
formation or appearance. Gag-PE fusions produced large irregular budded structures, up to 
450 nm across. The sequence of the polypeptide fusion appeared to have a greater influence on 
VLP formation than polypeptide length, possibly due to protein folding constraints. It would 
appear that chimaeric Gag fusions must be empirically tested for VLP formation, and that 
depending on the sequence composition, large C-terminal Gag fusions can produce chimaeric 
VLPs for vaccine purposes. This has important implications for candidate HIV -1 vaccine design. 
The ability to make particles with all or part of the protein sequence specified by a DNA vaccine 
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1.1 Overview 
Human immunodeficiency virus (HIV) was discovered in 1983 (Barre-Sinoussi et al., 1983), and 
has been identified as the main causative agent of acquired immunodeficiency syndrome (AIDS) 
in humans. HIV type 1 (HIV -1), HIV -2 and simian immunodeficiency virus (SIV) are all 
lentiviruses within the family Retroviridae, but it is the major (M) group of HIV-I (with 9 
subtypes: A-K, no E or I) that has been responsible for the vast majority of the ~2.8 million AIDS 
deaths worldwide in 2005 (UNAIDS, 2006). The greatest global disease burden due to the HIV 
pandemic is currently borne in sub-Saharan Africa (~64% of the ~39 million global infections 
(UNAIDS, 2006», where HIV-I subtype C (HIV-IC) predominates (IAVI, 2006). In developed 
countries, treatment of AIDS patients with highly active antiretroviral therapy (HAART) has 
proven successful in suppression of viral load and disease, thereby reducing mortality. However, 
the cost, the often sub-optimal distribution conditions and the uncertainty of supply pertaining in 
many sub-Saharan countries militates against the widespread use of antiretrovirals. Thus, the best 
long term solution to the HIV pandemic, particularly in these regions, is the development of safe, 
effective and inexpensive HIV vaccines (Burgers & Williamson, 2005; Nkolola & Essex, 2006). 
It is increasingly recognized that an effective vaccine against HIV will need to elicit broad cell 
mediated and humoral immune responses in both the mucosal and systemic components of the 
immune system (Lehner, 2003). To date, no single HIV vaccine candidate has been shown to 
prevent establishment of HIV infection (Letvin, 2005). However, a number of mixed vaccines are 
being investigated, with the common immunogen prime-boost design often yielding strong cell-
mediated immunological responses (McMichael & Hanke, 2003; Amara et al., 2001; Amara et 
al., 2005; Mwau et al., 2004; Smith et aI., 2004; Goonetilleke et aI., 2006). The prime has usually 
been a DNA vaccine, while boost antigens have included subunit proteins, live vectors and 
particle-based vaccines, with a promising candidate being HIV -1 virus-like particles (VLPs) 
based on the Gag structural precursor polyprotein (Young & Ross, 2003; Montefiori et ai., 2001; 
Jaffray et ai., 2004; Paliard et al., 2000; Doan et aI., 2005). Immune responses to Gag-based 
VLPs have been improved considerably by the incorporation of foreign antigenic proteins into 
the particle by two principal methods (Deml et al., 2005), and one type of chimaeric Gag VLP 










Chapter I : Literature Review 3 
1.1.1 HIV-1 virion and proviral genome 
The structural and regulatory proteins of HIV -1 have been extensively utilized as components in 
HIV -1 vaccines that have entered clinical trials (McMichael & Hanke, 2003), while the 
enzymatic proteins have been targeted by many therapeutic HIV -1 drugs (Pomerantz & Hom, 
2003). The position of structural proteins within the mature HIV -1 virion and the genetic 
organization of the proviral genome are detailed in Figure. 1.1. 
1.2 Rational design of HIV vaccines 
Despite enormous efforts worldwide for over 20 years, there is still no protective HIV -1 vaccine, 
and progress in vaccine design has been hampered by a number of challenges. The error-prone 
reverse transcription of the viral RNA genome results in an extraordinarily high mutation rate, 
which allows for escape mutants that avoid recognition by both arms of the adaptive immune 
response (McMichael & Hanke, 2003). A compounding factor is the genetic and geographical 
diversity of HIV-l subtypes, where prototype viruses have not been identified (Gaschen et al., 
2002). It is thought that vaccines may need to be directed at the predominant subtype within a 
given region to be effective (McMichael et ai., 2002). However, subtype specific vaccine design 
is further complicated by discrepancies between genotypes and immune properties (Nyambi et 
aI., 2000). Furthermore, the correlates of protection for HIV -1, including HIV -1 C, are not well 
defined (Pantaleo & Koup, 2004). Non-human primate models are also of limited use in 
evaluating how existing vaccine designs can be improved, since HIV does not replicate in these 
animals (Burgers & Williamson, 2005). 
The many attempts to generate vaccmes eliciting neutralizing antibodies (NAbs) to HIV-l 
isolates, primarily directed to regions of the envelope glycoprotein (Env, gp160), have been 
largely unsuccessful (Letvin, 2005; McMichael & Hanke, 2003). The third variable loop (V3) 
and CD4-binding domains (CD4BDs) of surface glycoprotein (gp120) have often been included 
in HIV -1 vaccines since these domains are recognized by antibodies that can neutralize HIV -1, 
albeit weakly or in an isolate-specific manner (Letvin & Walker, 2003). Although natural 
HIV-I infection does lead to HIV-specific antibody production, few of the sera can neutralize 
heterologous strains (Bojak et at., 2002). In the absence of NAbs that can broadly block viral 
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FIGURE 1.1. Schematic representation of the lflV-l proviral genome and mature virion. 
(A) The proviral genome (- 9.2 kb) is flanked by two long terminal repeats (LTRs). There are 9 open 
reading frames encoding a total of 15 possible proteins. The gag gene is translated into the structural 
Gag precursor (PrSSgag ) which is cleaved into matrix (MA), capsid (CA), nucleocapsid (NC) and p6 
(p2 and p I are spacer peptides). The pol gene is translated by a (-I) ribosomal frameshift as a Gag-Pol 
precursor polypeptide that yields the enzymes reverse transcriptase (RT), integrase (rN) and protease 
(PR) upon cleavage. The env gene encodes another structural precursor (Env, gp 160), which is cleaved 
into the surface (gp120) and transmembrane (gp41) glycoproteins. The regulatory (Nef, Tat, Rev) and 
accessory (Vpu, Vpr, Vit) proteins are encoded by spliced Env and Gag-Pol mRNAs. (8) In the mature 
HJV-I virion, MA forms a layer beneath the host-derived lipid bilayer, CA forms the conical core and 
NC coats the two copies of viral single stranded (ss) RNA genome. Trimeric glycoprotein spikes 
composed of gp120 anchored to the lipid bilayer membrane by gp41 are exposed on the virion surface. 
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Early containment of acute HIV infection coincides with HIV-specific CD8+ cytotoxic 
T-lyrnphocyte (CTL) responses (Koup et al., 1994; Letvin & Walker, 2003), which reduce viral 
load (Ogg et al., 1998) and suppress viraemia (Gandhi & Walker, 2002). In conjunction with 
recent evidence highlighting the importance of CTL responses in controlling HIV infection, focus 
has shifted from producing vaccines that elicit NAbs to those that stimulate broad, cross-subtype 
cell mediated responses (Bojak et at., 2002; McMichael & Hanke, 2003; Letvin, 2005; Nkolola & 
Essex, 2006). In addition, CD8+ CTL responses have often been favoured over CD4+ T-cell 
responses, since HIV replicates within CD4+ T cells. Nonetheless, there is evidence supporting 
the benefits of vaccine induced priming of CD4+ T-cell responses (Rosenberg et al., 1997) which 
improve the effectiveness of the CD8+ CTL response (Kalams et al., 1999). Ideally, vaccines 
should be designed to induce both systemic and mucosal responses, as HIV is spread venereally 
and through contaminated blood. Stimulation of innate immune responses further assists in 
combating infection and disease progression (Levy, 2001). Incorporating all these features into a 
single immunogen or into combination vaccine strategies remains a major challenge in HIV 
vaccine development. 
1.2.1 Components of HIV vaccines 
HJV -1 encodes 15 possible proteins (Fig. 1.1) and emerging vaccine designs for eliciting strong 
cell mediated responses have included components of Gag, Pol, Tat and Nef. The most conserved 
protein regions among HIV subtypes are within Gag and Pol, and cross-reactive anti-Pol and 
anti-Gag CTL responses are inversely correlated with disease progression (Ferrari et aI., 2000). 
Furthermore, defined epitopes recognized by CD8+ (Currier et at., 2002; Xu et al., 2002) and 
CD4+ (Boaz et al., 2003) T cells in HIV-l infected individuals have been identified in Gag. Both 
Tat and Nef induce strong cell mediated responses early in infection, and optimal CTL epitopes 
have been mapped in both of these regulatory proteins (Novitsky et al., 2001). This temporaly 
early immune activation may improve vaccine efficacy, and both these regulatory proteins are 
recognized as attractive vaccine components (Liang e/ al., 2002b; Goldstein, 1996). Tat is 
cytotoxic and induces cellular apoptosis, while Nef causes immune system dysfunction III 
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1.3 HIV vaccine strategies 
DNA vaccines, subunit vaccines (recombinant viral proteins or chemically synthesized peptides), 
live vectors (bacterial or non-HIV viruses carrying HIV proteins) and particle-based vaccines 
(inactivated virions, live attenuated vaccines, VLPs) have all been investigated as potential HIV 
vaccines (Giri et al., 2004; Bojak et aI., 2002; McMichael & Hanke, 2003; Young & Ross, 2003; 
Nabel, 2002; Letvin, 2005; Girard et aI., 2006). As part of a heterologous primelboost strategy, 
particle-based vaccines are complex antigens that can present a number of epitopes in a highly 
immunogenic formulation. Of these, VLPs are the most appealing in terms of safety and flexible 
vaccine design. 
1.3.1 Particle-based vaccines 
Inactivated vaccines 
For many years, inactivated HIV virions did not result in vaccines which generate CTL responses 
in animal models (Letvin, 2005) and the immunogenicity of Env was generally destroyed during 
the inactivation process, precluding NAb formation (Girard et aI., 2006). In a recent report, 
a combined chemical and physical inactivation strategy yielded HIV -1 virions that elicited 
modest titres of NAbs in non-human primates (Poon et aI., 2005). However, the possibility of 
incomplete virion inactivation cannot be discounted, in which case vaccine formulations could 
still contain infectious virions. This overriding safety concern is likely to prevent this vaccine 
strategy from entering clinical trials. 
Live attenuated vaccines 
Many studies have been conducted on live attenuated primate retrovirus vaccines, but the most 
encouraging results have been obtained from SIV -HIV (SHIV) viruses, which are generalized as 
recombinant SIVs displaying HIV-l Env. Live attenuated SHIV (neflvpr deleted) led to 
protection of rhesus macaques challenged with highly pathogenic SHIV-89.6P (Ui et aI., 1999). 
Analogously, sequential immunization of rhesus macaques with two SHIV vaccines (neflvpu 
deleted and then vpu deleted) conferred protection to mucosal challenge with a combination of 
SHIV and SIV challenge viruses (Kumar et aI., 2002). Despite such promising results, live 
attenuated vaccines for HIV have not been widely pursued (Girard et at., 2006) since the degree 
of attenuation seems inversely correlated with vaccine efficacy and protection from disease 
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and therefore the most promising vaccine candidates are also the least safe, with greatest risk of 
reversion to virulence. Additional caveats for live attenuated HIV vaccines include: 
(i) recombination with virulent forms, (ii) proviral integration into the host genome and 
(iii) disruption of immune system regulation (Young & Ross, 2003; lohnson, 1999). 
1.3.2 Virus-like particles (VLPs) 
VLPs can be generally defined as "self assembling, non-replicating, non-pathogenic genomeless 
particles of similar size and conformation to intact virions" (Young & Ross, 2003). VLPs have a 
number of safety, production and immunogenicity advantages over other HIV vaccine candidates 
(Noad & Roy, 2003; Doan et al., 2005; Deml et at., 2005). Primarily, they are non-infectious, 
lacking undesirable regulatory proteins or replicative genetic material (Deml et aI., 2005), and 
potentially can be produced to high yield and purity in heterologous expression systems. The 
particulate nature of VLPs (composed of structural proteins in a nati ve conformation) predisposes 
toward high immunogenicity (Doan et al., 2005; Persson et al., 1998; V zorov et al., 1991). 
Furthermore, VLPs appear to have intrinsic adjuvant properties (Michel et al., 1990), allowing 
them to stimulate both humoral and cellular immune responses in rodents and non-human 
primates, without extraneous addition of adjuvants (Wagner et al., 1996a; Paliard et aI., 2000; 
Buonaguro et al., 2002; Layton et al., 1993). In the context of HI V, VLPs are based on the Gag 
precursor polyprotein, which can also be used as a carrier of foreign antigenic proteins to make 
chimaeric VLPs that may improve VLP immunogenicity. 
1.4 PrSSgag VLPs 
The unprocessed HIV-l Gag precursor polyprotein, Pr55gag, is transported to the cell membrane, 
where it spontaneously assembles into particles which bud externally to form 100-120 nm VLPs 
(Fig. 1.2). Moreover, Pr55gag VLPs can form in the absence of all other HIV proteins (Gheysen et 
al., 1989), and have the same size, ultrastructural morphology and sedimentation properties as 
immature HIV virions (Wagner et al., 1992). Analogous features apply to SIV Pr57gag VLPs 















FIGURE 1.2. PrSSgag VLP formation. HIV-l gag is transcribed and translated into cytosolic Pr55Sag 
(Gag precursor protein) that is targeted to the inner leaflet of the cell membrane. Stable membrane 
binding facilitates the subsequent budding of enveloped VLPs (100-120 nm), which are released from 
the cell surface. The electron micrograph (from this study) shows the budding of Pr55gag VLPs from 
St21 insect cells (SpodopteraJrugiperda). Bar = 100 nm. 
1.4.1 Expression systems 
8 
Expression of PrSSgag in yeast spheroplasts (Sakuragi et at., 2002; Tsunetsugu-Yokota et aI., 
2003) and in mammalian cells using recombinant adenovirus (Vernon et aI., 1991), recombinant 
vaccinia virus (Wagner et aI. , 1992; Karacostas et aI., 1989; Haffar et aI. , 1990; von et aI., 1993; 
Hu et aI., 1990; Vzorov et aI. , 1991; Shioda & Shibuta, 1990) and rev dependent expression 
vectors (Mergener et aI. , 1992; Smith et aI. , 1990) has led to VLP formation and budding. 
Production of PrSSgag VLPs in insect cells USIng recombinant baculovirus has been widely 
reported (Tobin et aI., 1996b; Wagner et aI. , 1992; Gheysen et aI. , 1989; Royer et ai., 1991; 
laffray et ai., 2004). A range of transfer vectors and isolation procedures facilitate the easy 
generation and selection of recombinant baculovirus to express a gene of interest. Due to the 
availability of commercial reagents, advances in insect cell culture and amenability to scale-up; 
the baculovirus-insect cell expression system has been used for the routine production of 
numerous recombinant proteins (Kost et ai., 200S). This expression system is referred to in this 
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immunogenicity testing. Herein, the protease (PR) within Pol can be over-expressed by strong 
baculovirus promoters and lead to premature Pr55gag cleavage that prevents VLP assembly 
(Morikawa et aI., 1991; Hughes et at., 1993). Thus, for efficient VLP production in the 
baculovirus system, Pr55gag is usually expressed from only gag gene sequences, rather than 
the full gag-pol gene. 
1.4.2 Immunogenicity of PrSSgag VLPs 
Humoral responses to Pr55gag VLPs have been recorded in rabbits (Wagner et aI., 1992; Wagner 
et al., 1996b; Deml et at., 1997b) and rhesus macaques (Montefiori et al., 2001). The antibody 
ti tres in these studies were often high, but the sera were non-neutralizing. Vaccination of rhesus 
macaques with Pr55gag VLPs led to long lived CD8+ CTL responses against multiple epitopes in 
CA, NC and p6 (Paliard et al., 2000). Furthermore, numerous T-cell epitopes recognized by 
C08+ (Currier et al., 2002; Xu et ai., 2002), and C04+ (Boaz et al., 2002; Rosenberg et aI., 
1997) cells in HIV -1 infected individuals, have been identified in Pr55gag . In our research group, 
HIV -1 C Pr55 gag VLPs have been used successfully to boost the antibody and cellular immune 
responses in mice (Jaffray et al., 2004) and baboons primed with the DNA vaccine pTHgagC 
(R. Thomas, G. Chege, E. Shephard, E. Rybicki, A. Williamson, unpublished). 
Recent studies have indicated that VLPs can activate the innate immune system through 'danger 
signals' and lead to dendritic cell maturation and increased cytokine production (Tsunetsugu-
Yokota et at., 2003). This is thought to be a result of the particulate nature of VLPs and residual 
components of the cell expression system used in production. For example, baculoviral gp64, 
which is incorporated into the membrane of Gag VLPs produced in insect cells (Deml et al., 
2005), induces interferon production in mammalian cells (Gronowski et al., 1999). 
1.4.3 Safety of PrSSgag VLPs 
A number of studies have highlighted the relative safety of Gag-based VLPs compared to other 
particulate HIV candidate vaccines (Persson et at., 1998; Oem! et at., 2005; Doan et al., 2005; 
Young & Ross, 2003; Noad & Roy, 2003). The main concern which remains is that in the 
absence of genomic viral RNA, Gag VLPs can incorporate cellular RNAs from the expression 
system (Khorchid et al., 2002), contrary to an earlier report (Vzorov et at., 1991). Removal of the 
</>-site upstream of gag and disruption of the nucleic acid binding domains in NC has reduced the 
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The presence of minimal quantities of non-infectious RNA is certainly preferable in comparison 
to some of the formidable safety concerns associated with other particulate HIV vaccines (1.3.1) 
1.5 Pr55gag polyprotein precursor 
In natural HIV -1 infection, Pr55gag (translated from the gag gene, Fig. 1.\) is proteolytically 
cleaved during or immediately after budding into matrix (MA or p 17), capsid (CA or p24), p2, 
nucleocapsid (NC or p7), pi and p6 by the HIV -1 encoded PR (Henderson et aI., 1992) (Freed, 
1998). This processing is required for infectivity but not particle assembly or release (Rose et aI., 
1995). In the mature virion (Fig. 1.1), MA remains associated with the inner membrane surface 
while NC coats the genomic viral RNA within the CA core (Freed, 1998; Scarlata & Carter, 
2003). However, each domain has functions within the Gag precursor prior to maturation, and 
some of these also pertain to VLP assembly and release (Fig. 1.3). 
NTD CTD 
- aa 1 135 I 365 435 I I I 
PrSS gag ;II ~ I III III 
myr M MHR 
I I 
I IlL 
MA CA p2 NC pi p6 
(pI7) (p24) (p7) 
FIGURE 1.3. Minimal Gag domains involved in VLP formation. 
The Pr55gag polyprotein precursor is cleaved into MA, CA, p2, NC, pl and p6 during illY maturation. 
The positions of the M-, I-, L-domains along with the NTO, cm and MHR within CA are shown. 
Approximate amino acid (aa) positions are indicated, myr = myristyl moiety. Regions in orange have 
been shown to be essential for VLP formation, and those in purple may be replaced by functional 
heterologous sequences (1.5.2 and 1.5.3). White regions are thought to dispensable for VLP assembly, 




Myristylation of cytosol ic Pr55gag occurs co-translationally (Wilcox et aI., 1987) through the 
removal of the N-tenninal methionine and covalent attachment of myristic acid 
(CH3(CH2)12COOH) to g/y2 (Henderson et aI., 1992), which is conserved among HIV-l SUbtypes 
(Bryant & Ratner, 1990). Assembly and replication of HIV -1 are critically dependent on Pr55gag 
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1989; Bryant & Ratner, 1990). Mutation of the myristylation signal also prevents the budding of 
Gag VLPs from mammalian (Wagner et al., 1992) and insect cells (Wagner et al., 1992; Gheysen 
et al., 1989; Royer et al., 1991) as well as yeast spheroplasts (Sakuragi et al., 2002). 
Myristylation plays a central role in the targeting of Gag to the cell membrane (Freed, 1998; 
Scarlata & Carter, 2003), but it is not critical in this process since limited, weak membrane 
association occurs without myristylation (Bryant & Ratner, 1990). The primary function of 
myristylation is rather to facilitate the stable binding of PrSSgag to the cell membrane during 
virion and VLP assembly (Bryant & Ratner, 1990). This stable binding also requires a second 
signal consisting of basic residues in MA (Zhou et at., 1994; Spearman et al., 1997). Although 
myristylation is not directly involved in Gag multimerization (Morikawa et at., 1996), it has a 
key function in converting Gag multimers into Gag VLPs (Morikawa et al., 2000). 
Accumulated evidence suggests that a myristyl switch regulates the reversible binding of HIV-1 
Gag to membranes (Resh, 2004). In brief, Gag multimerization co-operatively exposes the 
myristyl moiety and enhances membrane binding prior to particle budding. Conversely, MA 
cleavage decreases membrane affinity, so that MA dissociates into the cell during infection. 
1.5.2 Assembly domains of Gag 
The roles of Gag proteins (corresponding to domains within Pr55gag) in the HIV-l life cycle are 
numerous and complex (Modrow et ai., 1994; Freed, 1998; Scarlata & Carter, 2003; Wills & 
Craven, 1991). Contradictory domain functions have been reported in different cell lines and 
expression systems, but the main differences are evident when comparing particle types, 
especially virions and VLPs. Only those functions involved in particle assembly and subsequent 
release are described here. 
1.5.2.1 Matrix (MA) 
An N-terminal basic domain in MA together with the myristyl moiety (the M-domain) regulate 
the targeting and binding of Pr5Sgag to the cell membrane (Spearman et al., 1994; Wang & 
Barklis, 1993) and appear to interact with membrane phospholipids (Zhou et al., 1994). However, 
this function can be carried out by replacing MA with a heterologous membrane targeting signal 
(Reil et al., 1998), and large C-terminal portions of MA have been removed without preventing 
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prevent virion assembly, provided a myristylation signal was retained (Accola et al., 2000; Lee & 
Linial, 1994). In several other studies of virion and VLP assembly, using different expression 
systems, deletions or mutations of MA regions have disrupted or abolished extracellular particle 
formation (Wagner et al., 1994a; Morikawa et ai., 1995; Spearman et at., 1994; Freed et al., 
1994), and both Gag assembly and targeting signals have been identified throughout MA 
(Freed et al., 1994). 
1.5.2.2 Capsid (CA) 
CA condenses into the mature virion core (Freed, 1998) and contains the highly conserved major 
homology region (MHR) which has been implicated in membrane affinity (Ebbets-Reed et al., 
1996). The N-terminal domain (NTD) of CA is required for mature core formation (Dorfman et 
al., 1994) and possible regulation of overall particle morphology (Reicin et al., 1996), but is not 
necessary for virion or VLP assembly (Wagner et al., 1994a; Borsetti et al., 1998; Wang & 
Barklis, 1993; Reicin et at., 1995). Conversely, the C-terminal domain (CTD) of CA (including 
MHR) is essential for HIV particle assembly (Kattenbeck et al., 1997; Borsetti et al., 1998; 
Dorfman et al., 1994; Mammano et al., 1994; Reicin et al., 1995; Zhang et al., 1996) and VLP 
formation (von et ai., 1993; Jowett et at., 1992; Kattenbeck et al., 1996). Furthermore, the 
C-terminal 11 amino acids (aa) of CA are involved in both Gag multimerization and membrane 
binding (Liang et al., 2003). 
1.5.2.3 Nucleocapsid ruC) 
A distinguishing feature of NC is the presence of two conserved cysteine-histidine boxes (or zinc 
finger motifs) for RNA packaging (Dorfman et at., 1993), which show a preference for ¢-site-
containing viral RNA (Amarasinghe et al., 2001). NC appears to aid in the tight packing of 
adjacent Gag molecules during particle assembly, since NC deletions resulted in low-density 
particles (Bennett et al., 1993). The N-terminal basic portion of NC, which contains an 
interaction (I)-domain, is responsible for self-interaction of Gag molecules (Zabransky et al., 
2002) but apparently not membrane binding (Ono et al., 2005) as previously proposed (Sandefur 
et al., 1998). NC, and the I-domain in particular, are implicated in HIV-l assembly (Dawson & 
Yu, 1998; Dorfman et al., 1993) and possibly in VLP formation as well (Jowett et at., 1992; 
Hoshikawa el aI., 1991; Gheysen et aI., 1989), although other studies showed that NC deletions 
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In addition, the I-domain function can be replaced by a leucine zipper (Accola et al., 2000; 
Zhang et al., 1998). The process of RNA packaging seems to concentrate Gag monomers and 
promote multimerization (Scarlata & Carter, 2003), but this is not required for VLP formation 
(Zhang & Barklis, 1997). 
1.5.2.4 p6 
The p6 region is the most variable domain in Gag, but contains a conserved proline-rich motif 
PT AP(P) within the late (L )-domain. This motif plays a crucial role in the release of mature HIV 
virions from the cell (Scarlata & Carter, 2003). Mutations throughout the L-domain severely 
impair virion budding, and assembled particles remain tethered to the exterior of human cells 
(Gottlinger et al., 1991; Freed, 2002). Subsequent studies confirmed this role ofp6 for detaching 
virions from the cell (Huang et al., 1995; Yu et al., 1995). The L-domain interacts with a host 
protein, Tsg 101, which is involved in the intracellular trafficking of membrane-associated 
proteins and exocytic pathways (Freed, 2002; VerPlank et al., 2001). Ubiquitin binding to 
Tsg101 is required for viral release (Goff et al., 2003). In other retroviruses, late domain 
functions have been identified (Freed, 2002) which can be functionally exchanged between 
unrelated Gag proteins (Parent et aI., 1995). A secondary late (L2)-domain (LXXLF) has been 
identified in p6 that binds a cellular protein AlP! (Strack et al., 2003), which like TsglOI, 
facilitates viral budding through the use of vacuolar protein sorting machinery. 
Despite this requirement for the L-domain in HIV maturation, p6 is not required for efficient 
Gag-VLP formation in the baculovirus system (Griffiths et aI., 1993; Royer et al., 1991; Jowett et 
al., 1992) or the vaccinia virus system (Spearman et at., 1994). An L-domain function was 
required for VLP release in HeLa cells (Accola et aI., 2000) but not in 293T cells (Wang et a!., 
1998) - although VLP production was low. Huang et al. noted that the requirement of p6 for 
virion release was suppressed when PR was inactivated (Huang et al., 1995), and that this may 
partly account for the results obtained when Gag was expressed alone for VLP production. In 
contrast, Accola et af. subsequently reported that the inclusion of p6 enhanced VLP production in 
the absence of PR processing (Accola et al., 2000). Therefore, the requirement of L-domains for 
particle release is apparently dependent on the expression system, cell type and the type of 
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1.5.2.5 Spacer regions, p2 and pi 
The CA-NC spacer, p2 (or SPI, 14 aa), is crucial in HIV assembly (Liang et aI., 2002a) and may 
be required for structurally ordered assembly of particles, Deletion of p2 has been shown to have 
no affect on Gag membrane binding (Guo & Liang, 2005), but led to heterogeneous sized virions 
(Krausslich et al., 1995) or tubular structures instead ofVLPs (Morikawa et al., 2000) or virions 
(Gross et aI., 2000). Mutations in p2 restricted both Gag multimerization and binding to cell 
membranes (Guo et aI., 2005), and have caused aberrant VLP structures (Accola et al., 1998). 
There are no reports to date on the functions of the NC-p6 spacer, pI (or SP2). 
1.5.3 Minimal Gag constructs for VLP formation 
The data available on the assembly domains of Gag indicates that large portions of gag can 
potentially be deleted without preventing Gag VLP formation. This has application in the design 
of chimaeric Gag VLPs, where dispensable regions for VLP assembly may be replaced by 
heterologous sequences. 
VLPs comprising C-terminally truncated Gag 
Two groups have produced p6-truncated HIV-l Gag VLPs using the baculovirus system (Royer 
et aI., 1991; Griffiths et al., 1993). Luo et al. expressed high levels ofVLPs using recombinant 
baculovirus from an HIV-2 gag gene without the overlapping pol sequence (Luo et aI., 1990). 
HIV -1 Gag C-terminal truncations including p2 (Fig. 1.1) abolished particle formation in insect 
(Gheysen et al., 1989; Morikawa et aI., 2000) and human cells (Accola et al., 2000) or yielded 
considerably reduced levels of particles (Wang et al., 1998) in human cells. 
Minimal Gag-containing VLPs 
Sequence between the myristyl anchor and MHR was shown to be dispensable for VLP 
formation in human cells (Borsetti et al., 1998), and limited VLPs were produced in the absence 
ofNC-pl-p6 (Wang et al., 1998). Based on this, and the knowledge of Gag domain functions in 
assembly (1.5.2), the minimal Gag regions required for VLP assembly can be estimated 
(Fig. 1.3). Accola et al. demonstrated that a 16 kDa Gag protein retaining only the myristylation 
signal and the C-terminus of the CA-p2 domain could form extracellular VLPs in human cells if 
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1.6 Chima eric Gag VLPs 
VLPs based on Pr55gag or truncated Gag derivatives are highly immunogenic particulate carriers 
for foreign (non-Gag) polypeptides. Two principal strategies have been defined for displaying 
antigenic epitopes and peptides (Deml et aI., 2005). Type I VLPs have foreign polypeptides 
included within the VLP as integrations or fusions with Gag, whereas type II VLPs have foreign 
proteins (primarily Env) incorporated into the outer surface of the Gag VLP (Fig. 1.4). The 
majority of type I VLPs have been produced by expressing heterologous sequences as in-frame 
insertions within gag or as in-frame fusions to the 3 ' -end of a gag gene. More recently, foreign 
sequences have been expressed in the Gag-Pol open reading frame as a result of ribosomal 
frameshifting (Tobin et ai., 1997). In this study, these different chimaeric Gag VLPs are referred 
to as: type II VLPs, type I frameshift VLPs and type I in-frame VLPs. Since the latter were the 
focus of this study, the preceding two are only described briefly for comparison. 
A B 
FIGURE lA. Type I and Type II cbimaeric Gag VLPs. 
(A) Type I VLPs are composed of Gag carrier proteins (blue) that contain foreign epitopes or 
polypeptides (orange). These can be inserted to replace deleted sequences within Gag that are not 
required for VLP formation, or fused to the C-terminus of full-length or truncated Gag. (8) Type II 
VLPs have Env proteins (brown) anchored to the outside of the particle by gp41 or a suitable 
transmembrane domain (grey). This nomenclature is based on work by Deml et al., 2005 . 
1.6.1 Type II VLPs 
Native HIV -1 Env, and derivatives thereof, can be incorporated into the host-derived membrane 
of VLPs by a suitable transmembrane domain, as occurs in HIV virions (Fig. 1.1). However, 
shedding of these Env proteins during VLP purification, due to unstable membrane anchoring, 
has been reported to reduce to the Env-specific immune responses to VLP preparations 
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Env components of type II VLPs 
Type II VLPs incorporating full-length gp 160, anchored by gp41 , have been produced in vaccinia 
(Vzorov et aI., 1991; Haffar et al., 1990) and baculovirus systems (Tobin et al., 1996a; Wagner 
et aI., 1994b). Env incorporation into VLPs is known to be dramatically increased by partial or 
complete deletion of the C-terminal cytoplasmic tail of gp 160 (Deml et aI., 2005) or by the use of 
heterologous membrane anchors (e.g. transmembrane domain of Epstein-Barr virus gp220/350 
(Oem! et al., 1997b; Deml et al., 1997a». These strategies also circumvent possible immune 
dysfunction attributed to gp41 (Ruegg et al., 1989). 
Immune responses to type II VLPs 
In addition to humoral and cellular responses to Gag, type II VLPs have stimulated both high 
titres of Env-specific antibodies and CTLs toward Env in mice (Buonaguro et al., 2005; 
Buonaguro et aI., 2002; Deml et al., 1997b), rabbits (Haffar et al., 1991; Wagner et al., 1996c) 
and rhesus macaques (Wagner et at., 1998). Furthermore the immune sera exhibited neutralizing 
activity toward homologous (Deml et at., 1997b; Wagner et al., 1998) and heterologous 
(Buonaguro et al., 2005; Buonaguro et al., 2002) HIV -1 isolates, unlike type I VLPs. Despite 
these promising immune responses, vaccination of rhesus macaques did not confer protection to 
SHIV infection (Wagner et al., 1998). 
1.6.2 Type I frameshift VLPs 
The Gag-Pol polyprotein (160 kDa) is translated through a (-1) ribosomal frameshift at the gag-
pol frameshift signal within NC, and occurs at a frequency of -5% (Jacks et at., 1988; Wilson et 
al., 1988). Therefore, pol genes are expressed as a fusion to a truncated Gag molecule, and CA is 
involved in incorporating Gag-Pol into HIV virion (Srinivasakumar et al., 1995) and VLPs 
(Smith et al., 1993). This process has been harnessed to create type I frameshift VLPs, where the 
DNA sequence encoding the foreign polypeptide is added downstream of gag in the same frame 
as pol. Using this method, only 5% or fewer of the Gag molecules in the resultant VLP would be 
expected to carry the extended protein sequence, which agrees with analyses of type I frameshift 
VLP protein content (Tobin et al., 1997; Buonaguro et al., 2001). 
It has been suggested that it is this lower molar ratio of chimaeric protein to Gag that allows 
frame-shift VLPs to accept larger peptide fusions than type I in-frame VLPs (Tobin et al., 1997). 










Chapter I: Literature Review 17 
(-160 kDa) construct (Buonaguro et al., 2001) and a Gag fusion to the C-tenninal 273 aa of HI V-
1 gp120 (Tobin et al., 1997). Young et al. constructed DNA vaccine plasmids that expressed 
large Gag-Pol chimaeras which were capable of fonning type I frameshift VLPs in primate cell 
lines (Young et aI., 2004). 
The Gag-Env frame-shift VLPs elicited CTL responses to both Gag and Env epitopes in mice, 
whereas humoral responses, albeit strong, were limited to Gag (Tobin et aI., 1997). There is no 
reported immunological data for the Gag-Pol-Nef frameshift VLPs (Buonaguro et a!., 2001) or 
those expressed by the DNA vaccines (Young et al., 2004). 
1.6.3 Type I in-frame VLPs 
A number of chimaeric Gag VLPs have been constructed by the direct incorporation of 
heterologous peptides into the Gag carrier, either to replace portions of PrSSgag that are non-
essential to VLP fonnation, or as fusions to a truncated Gag C-tenninus. This is accomplished by 
gene insertions or fusions in-frame with gag. These strategies are thought to pennit longer 
fusions than internal insertions (without replacement) or C-tenninal fusions to PrSSgag, both of 
which have been less successful in producing chimaeric VLPs (Luo et al., 1992; Tobin et at., 
1996a) and have not been as well investigated (Deml et al., 200S). In each case the fusion is in-
frame with gag. 
1.6.3.1 In-frame fusion positions and sequences 
Fusion sequences 
Approximately 80% of PrS5gag is dispensable for VLP assembly (Accola et al., 2000), which 
potentially allows for type I VLPs to be constructed with substantial lengths of heterologous 
antigen-encoding sequence. To date, however, only individual epitopes or short polypeptides 
have been either internally integrated or C-tenninally fused to Gag carriers. These short, 
immunogenic fusions have included a Nef-derived epitope (Wagner et al., 1994a; Wagner et al., 
1996c; Wagner et al., 1994c), the gp120 V3 loop (Griffiths et al., 1993; Luo et al., 1992; Wagner 
et a/., 1993; Wagner et al., 1996b; Wagner et al., 1994a; Truong et al., 1996; Brand et al., 1995), 
tandem V3 repeats (Luo et aI., 1998) and CD4BD derivatives (Luo et al., 1992; Truong et al., 
1996; Wagner et aI., 1994a; Wagner et al., 1996b). With the exception of a single Nef-derived 
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derived from gp 120 sequences, and all VLPs were produced in the baculovirus system 
(Table 1.1). In addition, a number of Gag constructs with V3 and CD4BD sequences within 
feasible replacement regions have failed to form VLPs in the baculovirus system (Table l.2). 
The available literature suggests that there is an upper limit of ~ 200 aa that can be fused in-frame 
to the C-terminus of Pr5S gag for correct assembly into VLPs (Deml et al., 2005). However, no 
successful attempt to test this length limit has yet been reported. Furthermore, it would appear 
that the nature and composition of the fusion sequence can affect VLP formation (Tobin et al., 
1996a; Deml et al., 2005), especially for longer fusions (Luo et al., 1992), although the 
parameters of permissible fusions have not been defined. 
Reported fusion positions 
As illustrated in Figure 1.3, a number of regions within Gag are dispensable for VLP assembly 
and offer potential positions for replacement of Gag sequence with foreign sequence. To date, 
segments within the CA NTD and the pI region (between the 1- and L-domains) have been 
replaced by in-frame heterologous sequences to form chimaeric VLPs (Table 1.1). These two 
particular sites within the feasible replacement regions of Gag are thought to have the highest 
probability of being exposed near the VLP periphery (Wagner et aI., I 994a). Fusions to 
C-terminally truncated Gag have also been successful in producing VLPs, particularly for longer 
fusion sequences (Table l.1). 
Fusion position affects VIP formation 
Two studies have indicated that the position of the in-frame fusion with Gag affects VLP 
formation (Luo et al., 1992; Wagner et al., 1994a). For example, Luo et al. incorporated HIV-1 
V3 (91 aa) or HIV -2 V3 (90 aa) as either inserts within MA or C-terminal fusions to an HIV-2 
Gag truncated in NC (Table 1.1). All four constructs expressed the chimaeric protein in 
recombinant baculovirus infected insect cells, but only the two C-terminal fusions produced 
VLPs (Luo et al., 1992). This suggested that Gag without internal replacement sequences was a 
superior antigen carrier for these fusions, and that C-terminal fusions may be a preferable design 
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TABLE 1.1 Chimaeric Gag constructs that have produced type I in-frame VLPs 1 
Fusion position 
size 2 f'usion derivative Gag carrier 4 inGag Reference 
(aa) (aa) 
11 CD4BD Pr55gag C-tenninus Tobinetal.,1996a 
21 Nef-derived CTL Gag(d211-241), 211, Wagner et af., 1994a 
epitope Gag( d436-471 ), 436, 
Pr55Gag C-tenninus 
23 CD4BD 3 Gag(d211-241), 211, Wagner et al., 1996b 
Gag( d4 36-4 71 ), 436, 
Pr55Gag C-tenninus 
26 Y3 Gag(dJ96-228) 196 Brand et aI., 1995 
Truong et aI., 1996 
36 Y3 3 Gag(d21 1-241), 211, Wagner et aI., 1996b 
Gag( d436-471), 436, 
Pr55gag C-tenninus 
40 Y3 HIY-1 Gag C-tenninus Griffithsetal.,1993 
(76 aa C-tenninal truncation) 
54 3 tandem copies of HIY-2 Gag C-tenninus Luo et al., 1998 
consensus Y3 (93 aa C-tenninal deletion) 
55 CD4BD Gag{d211-241), 21 I, Wagner et at., 1996b 
Gag( d436-471), 436, 
Pr55gag C-tenninus 
60 2 gpl20 + 2 gp41 H1Y-2 Gag C-tenninus Luo et aI., 1998 
epitopes (93 aa C-tenninal deletion) 
60 Y3 sequences from HIY-2 Gag C-tenninus Luo et af., 1998 
4 HIY-I strains (93 aa C-tenninal deletion) 
90 HIY-2 Y3 HIY-2 Gag C-tenninus Luo et at., 1992 
(93 aa C-tenninal deletion) 
91 Y3 HIY-2 Gag C-tenninus Luo et al., 1992 
(93 aa C-tenninal deletion) 
92 Y3 (37 aa) + Gag(d211-241/d436-471) 211 and 436 Wagner et at., 1996b 
CD4BD (55 aa) 
198 HIY-2 Y3 + CD4BD HIY-2 Gag C-tenninus Luo et aI., 1992 
(93 aa C-tenninal deletion) 
I All proteins were expressed in the baculovirus system, except the Gag-Nef fusion, which was 
expressed by recombinant vaccinia virus. All polypeptides were derived from HIY-I sequences 
unless otherwise indicated. 
Total number of aa if more than one fusion was present in the Gag carrier. 
3 Analogous constructs also expressed by recombinant vaccinia virus (Wagner et aI., 1994a) 
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TABLE 1.2 Chimaeric Gag constructs that did not produce type I in-frame VLPs J 
Insert 
Fusion 





21 0lef-derived CTL epitope Gag( d99-154) 99 Wagner et al., 1994a 
36 V3 Gag(d99-154) 99 Wagner et at., 1994a 
45 gp 41 fusion domain Pr55gag C-terminus Tobin et al., 1996a 
59 V3 Pr55gag C-terminus Tobin et al., 1996a 
90 HIV-2 V3 HIV-2 Gag 115 Luo et al., 1992 
(93 aa C-terminal deletion) 
91 V3 HIV-2 Gag 115 Luo et at., 1992 
(93 aa C-terminal deletion) 
194 V3 + CD4BD HIV-2 Gag C-terminus Luo et ai., 1992 
(93 aa C-terminal deletion) 
1 A II proteins were expressed in the baculovirus system, except the Gag( d99-154) carrier fusions, which 
were expressed by recombinant vaccinia virus. All polypeptides were derived from HIV-l sequences 
unless otherwise indicated. 
d deleted for that amino acid region 
1.6.3.2 Morphology and yield of type I in-frame VLPs 
MOIphology 
20 
Reports on type I Gag-Env VLPs indicate that they usually resemble Gag-only VLPs by electron 
microscopy (EM), but were often larger in size (Luo et al., 1992; Luo et ai., 1998; Wagner et al., 
1996b). In a study with V3- and CD4BD-derived sequences, all C-terminal fusions to Pr55gag 
formed uniform VLPs (100-140 nm across), whereas some internal Gag fusions formed VLPs 
with irregular morphology and greater range in size (100-250 nm). Formation of large, 
heterologous particles was not limited to a specific fusion sequence or replacement position 
within Pr55gag (Wagner et aI., 1996b). 
Yield in baculovirus system 
Type I in-frame VLPs expressed by recombinant baculovirus have been present in the culture 
medium at high yields, ranging from 5-20 mg/l depending on the fusion sequence and its position 
within Gag (Wagner et ai., 1996a; Wagner et ai., 1994c). However, internal fusions have given 
lower yields ofVLPs than C-terminal fusions (Wagner et aI., 1996b), and increasing the size of 
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1.6.3.3 Immune responses to t.xpe I VLPs 
Position affects the strength of humoral but not cellular responses 
Wagner et al. found that the magnitude of anti-V3 and anti-CD4BD humoral responses in rabbits 
was strictly dependent on the position of the replacements within Gag, whereas the CTL response 
magnitude in mice, for the same set of chimaeric VLPs, was not influenced by the replacement 
position (Wagner et al., 1996b). Therefore, antigen processing for MHC class I epitope 
presentation is probably independent of the epitope position within the context of the Gag carrier. 
Although overall antibody responses were weak for these Env-derived epitopes, the highest 
antibody titres were detected for C-terminal fusions. 
Effect of adjuvants on immune responses to type I VLPs 
Although Gag-based VLPs can elicit immune responses in the complete absence of adjuvants 
(1.3.2), both aluminum hydroxide and Freund's incomplete adjuvant have been administered with 
type I in-frame VLPs in immunogenicity studies. Neither improved the V3 antibody titre or 
neutralizing ability in rats and rabbits (Griffiths et al., 1993; Wagner et al., 1996a; Wagner et al., 
1996b). In addition, both adjuvants have been shown to decrease the CTL response in mice 
(Griffiths et ai., 1993; Wagner et ai., 1996b). This down regulation of in vivo CTL responses in 
the presence of adjuvants has also been reported for hepatitis B virus surface antigen particles 
(Schirmbeck et aI., 1994). 
Humoral responses to type I VLPs 
Gag-V3 VLPs have elicited antisera in rabbits that neutralized homologous HIV infectivity where 
Gag-only VLPs did not, indicating that the neutralization activity was due to V3 specific 
antibodies (Luo et ai., 1992). However, similar experiments with other type I Gag-Env VLPs 
generated Env-specifk antisera with only very weak neutralizing activity (Wagner et aI., 1996b; 
Luo et aI., 1998). Synergistic effects from VLPs containing both V3 and CD4BD fusions, 
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Immunization of rats with Gag-V3 VLPs also produced weak V3 specific antibodies (Griffiths et 
aI., 1993), and in mice Gag-Env VLPs elicited weak anti-Env responses without neutralizing 
ability (Truong et al., 1996). In the cases where low antibody responses to Env were observed, 
there was a strong anti-Gag antibody response (Griffiths et al., 1993; Wagner et al., 1996b; 
Wagner et al., 1996a), and Gag may exert an immunodominant effect over Env. Alternatively, 
the heterologous fused epitopes were not sufficiently exposed to permit efficient B-cell 
interactions. 
eTL responses to type I in-frame VLPs 
Type I in-frame VLPs have elicited strong CTL responses in mice to V3 and CD4BD fusion 
sequences to Gag (Wagner et al., 1996a; Wagner et al., 1996b; Wagner et al., 1993; Griffiths et 
al., 1993; Schirmbeck et at., 1995). Furthermore, CTL responses have been detected after a 
single, low dose (0.1 p,g) of purified particles (Wagner et al., 1993), indicating the potential for 
CTL responses to be efficiently primed. Although some Gag-V3 VLPs have stimulated HIV-l 
isolate specific CTL responses in mice (Griffiths et al., 1993), VLPs carrying 3 tandem copies of 
a consensus V3 domain elicited a broad, cross-reactive CTL response in mice to four different 
strains of HIV -1 (Luo et at., 1998), and this is promising for HIV vaccine development. 
1. 7 Study outline and objectives 
The primary objective of this study was to make type I in-frame VLP analogues to the DNA 
vaccines pTHr.HIVA (Hanke & McMichael, 2000) and pTHLgrttnC (Burgers et al., 2006), 
which could be used in future prime-boost vaccine strategies. These chimaeric Gag VLPs would 
be produced using the baculovirus system and characterized by western blot and electron 
microscopy. Both of these DNA vaccines express chimaeric Gag-derived proteins with 
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In the case ofpTHr.HIVA, an exact analogue is impossible since the MA and CA domains in gag 
have been reversed in the DNA vaccine (Hanke & McMichael, 2000). Therefore, the closest VLP 
analogue would be an in-frame fusion of the HIV-IA CTL polyepitope (PE, 155 aa) to the 
C-terminus of a truncated Gag carrier molecule that is still capable of forming VLP. For 
pTHr.grttnC, an exact VLP analogue would necessitate fusing a 778 aa polyprotein (RTTN) to a 
p6-truncated Gag (Pr50gag) carrier molecule. However, the use of a full-length Gag carrier 
(Pr55gag) has the advantage of the inclusion of an increased number of potential Gag epitopes. 
It has been suggested, but not demonstrated until this study, that the maximum length of antigen 
that can be incorporated into a type I in-frame VLP is at most around 200 aa (Deml et al., 2005). 
Therefore, a broader objective of this study was to test the upper length limit of polypeptide that 
could be tolerated within a Gag-based VLP. To this end, PE and five sequences of differing 
length derived from RTTN were fused in-frame to the C-terminus of either Pr55gag or Pr50gag, 
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2.1 INTRODUCTION 
The overall objective of this study was to produce chimaeric Gag VLPs (to be tested as candidate 
HIV -1 vaccines) using a baculovirus system. HIV -1 subtypes A and C protein-encoding 
sequences were derived from the DNA vaccine plasmids pTHgagC (van Harmelen et al., 2003), 
pTHr.grrtnC (Burgers et al., 2006) and pTHr.HIVA (Hanke & McMichael, 2000). All coding 
sequences in these plasmids express proteins that have been functionally inactivated by mutation, 
as a safety precaution. A selection of gene fragments corresponding to additions of 113 - 778 aa 
were cloned as C-terminal fusions to either a full-length or p6-truncated gag gene in a donor 
vector (pFastBac ™Oual). In total, 17 proteins (detailed in Fig. 2.10) would be expressed in insect 
cells by recombinant baculovirus to assess chimaeric Gag VLP formation. 
C -terminal fusions to Gag were chosen over internal insertions since the longest successful 
fusions reportcd to date were achieved using this approach (Luo et al., 1992), and a review of the 
available literature suggests that continuous Gag sequences (without internal sequence 
disruptions) may be superior antigen carriers (1.6.3.1). Furthermore, the magnitude of CTL 
responses was not affected by the position of a V3 sequence within a Pr55gag carrier, whereas 
antibody responses were highest for C-terminal fusions (Wagner et al., 1996b). Since the 
flanking residues in this case did not affect the exogenous antigen processing for MHC class-I 
presentation, it seems reasonable to assume this may extend to other antigenic inserts. C-terminal 
fusions also produced a higher yield of VLPs with less size variation than internal insertions 
(Wagner et at., 1996b). 
The inclusion of a p6-truncated gag was based on the hypothesis that a smaller Gag carrier 
moiety that forms VLPs by itself (Royer et al., 1991) may be capable of tolerating larger fusions 
within the VLP structure than Pr55 gag. Other regions dispensable for VLP formation (Fig. 1.3) 
were not deleted so as to maintain maximum immunogenicity of the Gag carrier. Furthermore, 
minimal Gag constructs (1.5.3) often produced lower VLP yields than intact Gag sequences 
(Borsetti et al., 1998; Accola et ai., 2000; Wang et ai., 1998). 
The gag carrier genes contain the myristylation signal (ATGGGT, myr+) to facilitate Gag-only 










Chapter 2: Construction of recombinant Gag donor vectors 26 
have an abrogated myristylation signal (ATGGCT, myr-). The corresponding myristylated and 
non-myristylated proteins are designated Myr~ and Myr respectively. 
HIV codon usage differs substantially from that of most human genes and is characterized by a 
high AT content (Kypr & Mrazek, 1987). Human codon optimized (humanized) gag gcnes have 
shown 10-fold (Smith et al., 2004), 20-fold (Kofman et af., 2003) and 103-fold (zur Megede et 
al., 2000) increases in transient Gag expression relative to the native gene in human cells. 
Consequently, a number of HIV-l DNA vaccines, including pTHgagC, pTHr.grttnC and 
pTHr.HIVA use humanized sequences (van Harmelen et af., 2003; Burgers et aI., 2006; Hanke & 
McMichael, 2000). Therefore, humanized gag, with 76% nucleotide (nt) identity to wild-type 
(WT) gag, was used in all chimaeric constructs consistent with the vaccine fusion sequences. 
Although there are no reports in the literature on humanized gag expression in the baculovirus 
system, it has been shown in our laboratory that a humanized human papillomavirus type 16 L1 
capsid protein gene expressed at significantly higher levels in insect cells than the non-optimized 
gene (A. Hopkins, unpublished). 
2.1.1 Gag control constructs 
The Gag controls included in this study were: wild-type Gag (WTgagC), full-length humanized 
Myr+ Gag (HMgagC = Pr55gag), p6-truncated humanized Myr+ Gag (THMgagC = Pr50gag) and 
Myr versions of both humanized Gag proteins (H8MgagC and TH8MgagC). WTgagC was 
incorporated to compare expression with HMgagC, while THMgagC was included because 6 out 
of the 12 chimaeric Gag constructs contain this truncated form of Gag. It has been shown that 
Myr- Gag does not form VLPs, irrespective of the presence of p6 (Royer et al., 1991), and so 
H8MgagC and TH8MgagC are the negative controls for VLP production in insect cells 
expressing Gag-based constructs. 
2.1.2 Immunogenic components of Gag chimaeras from HIV-1 DNA vaccines 
Sequences encoding portions of an HIV-IC polyprotein (GRTTN) and an artificial HIV-IA 
immunogen (HIVA) were chosen for inclusion in chimaeric VLPs. Expression of both GRTTN 
and HIV A from the respective DNA vaccines has generated encouraging immune responses 
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2.1.2.1 RT -Tat-Nef (RTTN) derivatives 
The candidate HIV-IC DNA vaccine pTHr.grrtnC encodes GRTTN - a polyprotein comprising 
p6-truncated Gag (Myr-), inactivated reverse transcriptase (RT), shuffled Tat and inactivated Nef 
(TN), where the gene sequences were derived from the HIV -1 C vaccine strains Du 151 and 
Du422 (Burgers et al., 2006). These strains were selected as having the closest amino acid 
similarity to a South African subtype C consensus sequence (Williamson et al., 2003). The 
portion of the polyprotein C-terminal to p6-truncated Gag is collectively termed RTTN, and the 
components have been modified, at the genetic level, to be non-functional for stability and safety 
considerations (Burgers et al., 2006). Briefly, the active site of RT was inactivated by mutation 
(YMDDL ~ YMAAL), Tat was inactivated through shuffling of the three gene regions known to 
be important to function (while maintaining all potential epitopes) and Nefwas inactivated by the 
removal of 30 base pairs (bp) at the 5' -end. Vaccination of mice with pTHLgrttnC led to the 
induction of high CTL levels against multiple GRTTN epitopes, and strong IFN-y responses to 
RT were stimulated (Burgers et al., 2006). 
2.1.2.2 HIV -I A CTL polyepitope (PE) 
The HIV A immunogen (Hanke & McMichael, 2000) consists of SUbtype A consensus amino acid 
sequence of p24 and p 17 (cloned in the reverse order to p 17-p24 in native Gag) coupled to a 
string of overlapping CTL epitopes at the C-terminus. This HIV-IA CTL polyepitope (PE) was 
designed to induce CD8+ CTLs and includes 23 partially overlapping HIV -1 A-derived CTL 
epitopes (8-11 aa) identified in Kenyan patients infected with HIV -1 A. These epitopes, which are 
presented by 17 different HLA alleles (MHC class I restriction), were derived from Nef (8), 
Gag (7), Pol (6), and Env (4); many are conserved among HIV-J subtypes or are 
immunodominant. Two non-HLA epitopes for SlY Gag and HIV Env, recognized by macaque 
and murine CTL respectively, were included for use in quality control and potency assays. 
Finally, the C-terminal residues IPNPLLGLD derived from the simian virus 5 (SV5) capsid 
protein are recognized by the SV5-Pk monoclonal antibody (mAb), which allows for detection 
and quantification of the full-length peptide (Hanke et al., 1992). Expression of HIVA from the 
DNA vaccine pTHr.HIV A and a modified vaccinia virus Ankara (MVA) vector elicited HIV-
specific CTL responses in mice (Hanke et ai., 2002), rhesus macaques (Wee et al., 2002) and 
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2.1.3 Donor vector: pFastBac H1Dual 
In this study, Gag and chimaeric Gag sequences to be expressed by recombinant baculovirus 
were assembled in the donor vector pFastBac™Dual (Appendix C). The baculovirus used was 
Autographa californica nuclear polyhedrosis virus (AcNPV), and the method used to generate 
recombinant AcNPV (rAcNPV) from a donor vector is detailed in Figure A.I (A.S). Genes can 
be cloned into pFastBac TMDual to express proteins under the pI 0 promoter or the stronger 
polyhedron promoter (pPolh). Each promoter has a downstream multiple cloning site (MCS). 
2.1.4 Chapter aims 
The aim of the work reported in this chapter was to construct a set of donor vectors to generate 
rAcNPV expressing chimaeric IIIV -1 Gag proteins of various lengths and sequence 
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2.2 MATERIALS AND METHODS 
2.2.1 Site-directed mutagenesis and plasmid construction 
The HIV -1 subtypes A and C DNA sequences used in this study were derived from plasmids 
shown in Table 2.1. The polymerase chain reaction (PCR) conditions and temperature profiles for 
site direct mutagenesis (Fig. 2.1 & 2.2) are given in Appendix B, while the associated primers are 
listed in Table 2.2. A number of sub-clones were constructed (Fig. 2.3 & 2.4) to facilitate the 
manipulation and cloning of gag sequences necessary for the construction of Gag and chimaeric 
Gag donor vectors (Fig. 2.5-2.9). 
All DNA preparations and manipulations were carried out according to standard procedures 
(A.3). Cloning into pGEM:Ii! - T Easy was done according to manufacturer's instructions. All 
pFastBac n1Duai constructs contain HIV -1 protein encoding sequences cloned into the MCS of 
pPolh, where the complete protein-encoding sequences have start and stop codons. 
TABLE 2.1. Parental plasmid, DNA vaccines and cloning vectors used in this study 





I pGEM@ T Easy 
Hi pFastBac . Dual 
Sequence of interest / Reason for use 
WT, Myr+HIV-ICGaggene 
Full-length, humanized, Myr- HIV-IC Gag gene 
Polygene encoding Myr- p6-truncated HIV-IC Gag, reverse 
transcriptase (RT), shuffled Tat and inactivated Nef(TN). 
H IV -I A CTL polyepitope (PE) encoding sequence. 
Used for cloning of PCR generated products. 
Used for cloning protein sequences to be transposed into 
baculovirus. 
Source I Reference 
A. Jaffray2 
van Harmelen et at., 2003 
Burgers et at, 2006 
Hanke & McMichael, 2000 
Prom ega 3 
Invitrogen 4 
1 Both pTHgrrtnC and pTH.HIV A contain the ,6-lactamase gene (conferring ampicillin resistance), which 
was removed when manufactured for clinical trial (designated pTHr.grrtnC and pTHr.HIVA respectively) 
2 Department of Molecular and Cell Biology, University of Cape Town, Rondebosch 7701, Cape Town, 
South Africa. 
3 Prom ega Corporation, Madison, USA . 
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TABLE 2.2. Oligonucleotide primers used in plasmid construction and DNA sequencing 











S'-CTT GCC ACC ATG GGT GCTCGC GCA TC-3' 
5'-GGT GTC CTC CCA CTG TTC AGC ATA GTG TTC-3' 
5' -ATT AGG ATC CAA GCT TGC CAC CAT GGG TGC-3' 
5'-GCG AAG GCG CCA CTC CTC-3' 
5'-CTT GAA TTC TTG GCT GAG GGG GTC GCT AC-3' 
5'. AGC GAA TTC TT A GCC AGG GCG GCC CTT A TG-3' 
5'-TAA AGG TCC GTA TAC TCC GG·3' 







DNA sequencing Sense 
DNA sequencing Sense 
I Oligonucleotide primers were synthesized by the DNA Synthesis Service, Department of Molecular and 
Cell Biology, University of Cape Town; with the exception of HMgagRl (obtained from J. van Harme1en) 
Regions to introduce restriction enzyme sites and stop codons are in bold and underlined respectively. 
2.2.2 Plasmid verification 
2.2.2.1 DNA SeQuencing 
Inserts in all pGEMC!!: - T Easy constructs were sequenced in both directions using a pUC/M13 
sequencing primer set (Promega). All pFastBac™Dual constructs where blunting reactions were 
included in construction were sequenced in duplicate with the primer HMgagS 1 to confinu the 
sequence near the blunting site. In addition, pFBD-HfiMgagC and pFBD-THfiMgagC were 
sequenced in duplicate with the primer FBDS 1 to confinu the presence of the myr signal at the 
5' end of gag. Details of sequencing reactions are supplied in Appendix A,4. 
2.2.2.2 Restriction enzyme digest patterns 
The veracity of each plasmid was confinued by appropriate restriction enzyme digestion of 
small-scale DNA preparations (Appendix D). The banding patterns were visualized by 
electrophoresis through 0.8% agarose gels (Sambrook et al., 2001) and compared to the expected 
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2.3 RESULTS 
Seventeen donor vectors to generate rAcNPV that express control and chimaeric Gag proteins 
(Fig. 2.10) in insect cells were constructed. 
2.3.1 Site-directed mutagenesis 
The WT HIV-IC gag in pGEMgaglOMl contains the myr+ signal whereas the humanized gag in 
pTHgagC does not. Site-directed mutagenesis restored the myr+ signal and inserted a BamHI site 
at the 5' -end of humanized gag (Fig. 2.1). PCR amplifications (Fig. 2.2) were also used to insert 
a stop codon within gag to generate the 3' -end of p6-truncated gag (3 'THgag), and to remove the 
stop codon at the 3' -end of full-length gag (3 'HgagNS). DNA sequencing confirmed that the 
desired mutations were achieved without any errors. 
2.3.2 Cloning strategies 
2.3.2.1 Sub-clones 
The PCR products 5'HMgag (Fig. 2.1B), 3TIgagNS (Fig. 2.2, lane 1) and 3'THgag (Fig. 2.2, 
lane 2) were cloned into pGEM® - T Easy for the construction of 3 further pFastBac™Dual 
sub-clones (Fig. 2.3 & 2.4). 
2.3.2.2 Gag control donor vectors 
The cloning strategies for the construction of the five Gag control donor vectors are shown in 
Figures 2.3-2.6. These donor vectors facilitate the generation of rAcNPV expressing 3 positive 
Gag VLP controls (WTgagC, HMgagC and THMgagC) and 2 negative Gag VLP controls 




















FIGURE 2.1. Site-directed mutagenesis to restore the myr+ signal and introduce a BamHI cloning 
site upstream of gag. (A) PCR amplification of the 5 ' end of gag (5'HMgagI, 583 bp) in pTHgagC 
with primers HMgagFI and HMgagRI restored the myr+ signal (ATGGCT ~ ATGGGT) at the 
5' -terminus of the gene, (8) PCR amplification of 5 ' HMgagI with primers HMgagF2 and HMgagR I 
introduced a BamHl cloning site upstream of the gag start codon (5'HMgag, 596 bp) . " = Lambda 




FIGURE 2.2. Site-directed mutagenesis to add and remove stop codons within gag. 
PCR amplification of the 3' -region of gag in pTHgagC with primers HMgagF3 and HMgagR2 
removed the stop codon and introduced an EcoRi site (3 'HgagNS, 968 bp), lane I. A stop codon 
(TAA) and an EcoRl site were inserted within a 3 'gag region upstream of the p6 encoding sequence 
using primers HMgagF3 and HMgagR3 (3'THgag, 821 bp), lane 2. " = Lambda DNA-PstI MW 
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FIGURE 2.3 . Construction of a donor vector to generate rAcNPV expressing full-length 
humanized Gag. The HlY -I C humanized, myr+ gag gene (HMgagC) was assembled into the 
pFastBac™Dual donor vector under pPolh (yellow box); black boxes represent relevant antibiotic 
resistance genes. Genes expressing Gag are shown as blue arrows. The sub-clone pFBD-S'HMgag was 
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Dig,,""' WlrOd ~d &oRI 
Ligation of fragments (803, 953 and 806 bp respectively) with Narl / EcoRJ digested pFBD-SoHMgag 
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'--~----------------------~ 
Gag-cbimaera vectors 
Used to generate all chimaeric Gag donor vectors 
FIGURE 2.4. Construction of Gag-chimaera vectors and a donor vector to generate rAcNPV 
expressing THMgagC. The HJY-IC p6-truncated, humanized, myr+ gag gene (THMgagC) was 
assembled into the pFastBac™Oual donor vector under the pPolh (yellow box); black boxes represent 
relevant antibiotic resistance genes. Genes expressing Gag, RT, TN are blue, red and green 
respectively. The Gag-chimaera vectors harboring gag sequences without stop codons (NS) were used 





























Digestion with Narl and Hindlll 
/t~ 









FIGURE 2.5. Construction of donor vectors to generate rAcNPV expressing Myr - Gag proteins. 
The HIV-IC full-length and p6-truncated, humanized, my,.- gag genes (fMMgagC and TH~gagC) 
were assembled into pFastBac™Dual under pPolh (yellow box); black boxes represent relevant 
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FIGURE 2.6. Construction of a donor vector to generate rAcNPV expressing WT Gag. 
The HIV -\ C myr+ WT gag gene (white arrow) was cloned into the pFastBac TMDual donor vector 
under pPolh (yellow box), black boxes represent relevant antibiotic resistance genes. The functional 
gene (in the donor vector) expressing Myr+ WT Gag (WTgagC) is shown as the light blue arrow. 
2.3.2.3 Chimaeric Gag donor vectors 
36 
All 12 donor vectors for the generation of rAcNPV expressing chimaeric Gag proteins were 
constructed by cloning selected in-frame HIV -1 DNA sequences into the Gag-chimaera vectors 
(Fig. 2.7-2.9). These donor vectors represent 10 RTTN-derived Gag fusion constructs and two 
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FIGURE 2.7. Construction of donor vectors to generate rAcNPV expressing Gag-3'RT and 
Gag-PE chimaeras. The 3' -end of the RT gene and the PE encoding sequence from the DNA 
vaccines pTHgrttnC and pTH.HlV A were cloned into the Gag-chimaera vectors under pPolh (yellow 
box); black boxes represent relevant antibiotic resistance genes. 3 'RT was blunted with mung bean 
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FIGURE 2.8. Construction of donor vectors to generate rAcNPV expressing Gag-3'TN and 
Gag-TN chimaeras. The 3'-end of the TN gene (encoding only Nefsequence) and the full TN gene 
from pTHgrttnC were cloned into the Gag-chimaera vectors under pPoth (yellow box); black boxes 
represent relevant antibiotic resistance genes. 3 'TN and TN were blunted with Klenow enzyme. Genes 
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FIGURE 2.9. Construction of donor vectors to generate rAcNPV expressing Gag-RT and 
Gag-RTTN chimaeras. The RT gene and the concatenated RT and TN genes from pTHgrttnC were 
cloned into the Gag-chimaera vectors under pPolh (yellow box); black boxes represent relevant 
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2.3.3 Control and chima eric Gag constructs 
The 17 donor vectors (2.3.2) each contain regions encoding either a Gag control protein or a 
chimaeric Gag fusion. The expected molecular weights of these full-length proteins and the 
number of amino acid residues in C-terminal fusions are summarized in Figure 2.10. 
2.4 DISCUSSION 
The recombinant Gag donor vectors constructed in this study allow for the possible expression of 
17 different Gag-based proteins in insect cells by rAcNPV. The principle function of this vector 
set was to generate potential HIV -1 vaccine candidates and simultaneously test the size limit 
(up to 778 aa) of C-terminal fusions to Gag that still permit VLP formation. To this end, fusion 
sequences from two existing HIV -1 DNA vaccines were chosen, so that any chimaeric VLPs 
produced would potentially be superior to Gag-only VLPs in terms of antigenicity. Furthermore, 
particulate protein analogues to these DNA vaccines could be used in prime-boost strategies to 
enhance immune responses. 
Apart from providing internal experimental controls, the Gag control donor vector set allows for 
a number of features of Gag expression in the baculovirus system to be investigated, which 
includes the following: Evaluation of the effect of human codon optimization on Gag expression 
by quantitative comparison of WTgagC and HMgagC levels in cell lysate and culture 
supernatant. Determination of the influence of p6 on Gag expression, VLP production and 
particle morphology by analysis of HMgagC and THMgagC expressing cells. Determining the 
expression levels, cellular distribution and structures formed by Myr- Gag relative MyrT Gag. 
Inclusion of PrSSgag and PrSOgag Myr versions may elucidate whether the role of p6 changes in 
the absence of a myr+ signal. 
Furthermore, all the pFastBac TMDual donor vectors contain protein-encoding sequence under the 
control of pPolh, leaving the p 10 promoter available for insert cloning. An application of this 
would be to express HIV-l Env (or a suitable Env-derivative) under pIa, thereby allowing type I 
in-frame VLPs that also incorporate Env components in the VLP membrane to be produced from 
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However, it may still prove preferable to co-express Env under pPolh in a separate donor vector, 
since pPolh is a stronger promoter than pI 0 and the optimal infection conditions of each 
corresponding recombinant baculovirus could be determined separately. 
Finally, the Gag-chimaera vectors constructed in this study provide a general backbone for 
constructing donor plasmids encoding C-terminal Myr+ Gag fusions. Genes of interest can be 
cloned in-frame into the pPolh MCS between the EcoRI and HindIII restriction enzyme sites to 
express chima eric Gag proteins. In addition to antigenic sequences for candidate Gag-based VLP 
vaccines, reporter genes or fluorescent markers could be inserted to investigate biochemical 
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FIGURE 2.10. Schematic representation of control and chimaeric Gag constructs. 
Each Gag and Gag-fusion encoding DNA sequence was cloned into pFastBac™Dual under pPolH. The 
corresponding full-length proteins to be expressed by rAcNPV are shown with the N-terminus on the left. 
Chimaeric Gag constructs are arranged in ascending order of C-terminal fusion size. 
Construct nomenclature: WT = wild-type, T = p6-truncated (~p6) Gag, H = humanized, M = Myr+ 
(gly2), ~ = Myr- (ala2), C = HIV-IC derived, PE = HlV-IA CTL polyepitope, RT = HlV-IC reverse 
transcriptase with mutated active site, TN = HIV-IC epitope - shuffled Tat and inactivated Nef, 3'RT = 
product from 3' end of RT gene, 3 'TN = product from 3' end of TN gene, containing only Nef sequence 
(nomenclature for 3 'TN reflects the method of construction and is consistent with that for RT and 3 'RT). 
Legend: aa, amino acid; kDa, kilo Dalton; MG, metlgJy2; MA, metlala2. 
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3.1 INTRODUCTION 
The baculovirus system (1.4.1) has a number of advantages over other heterologous protein 
expression systems (Kost et aI., 2005; Hu, 2005). These include high protein yields, potential for 
large gene insertions, biosafety (non-infectious to humans), the eapacity to produce complex 
quaternary structures and the ability to perform some higher eukaryotic post-translational 
modifications - including phosphorylation and myristylation. These two modifications in 
particular are important in the context of HIV Gag expression for VLP production. A number of 
VLPs from other viruses, including human papillornavirus, hepatitis C virus, parvovirus, 
polyomavirus, herpes simplex virus and severe acute respiratory syndrome corona virus have also 
been produced using recombinant baculovirus (Hu, 2005). 
3.1.1 Assessing VLP formation 
Gag assembly domains and the production of Gag-based VLPs have both been extensively 
studied in insect cells using baculovirus expressed proteins (1.4.1). In this system, the presence of 
Gag-based proteins in the culture supernatant, following recombinant baculovirus infection is a 
necessary but not sufficient criterion for determining whether extracellular VLPs have been 
fornled. Although myristylation of Gag is essential for VLP budding and release from insect cells 
(Wagner et al .. 1992; Gheysen et al., 1989; Royer et aI., 1991), Myr+ Gag can be released from 
these cells in a soluble, non-particulate form (Royer et ai., 1992). Furthermore, even Myr Gag is 
released from insect cells in this soluble form (Royer et al., 1992) and cell lysis (increased by 
baculovirus infection) causes the further release of both intracellular protein aggregates and 
soluble proteins into the culture medium. The localization of Gag-based proteins to the cell 
membrane is a necessary but not sufficient condition for extracellular VLP formation. Although 
stable membrane binding of Myr Gag to the cell membrane is essential for VLP assembly 
1.2), some Myr+ Gag truncations (Gheysen et aI., 1989) and in-frame Myr+ Gag-V3 fusions 
(Tobin et al., 1996a) have localized to insect cell membranes and not formed VLPs. 
3.1.2 Expression and proteolysis of Gag proteins in insect cells 
The expression of Gag proteins in recombinant baculovirus-infected insect cells is regulated 
primarily at the level of transcription (Royer et al., 1992). Post-translational events including 
VLP assembly and extracellular protein release were not found to influence the level of Gag 
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During HIV virion maturation, PrSS gag is cleaved into the mature Gag proteins (MA, CA, NC, p6) 
and two smaller peptides (p 1 and p2) by the viral PR «Freed, 1998). However, insect cell and 
baculovirus proteases also process PrSSgag (Wagner et al., 1992) and chimaeric Gag proteins 
(Wagner et al., 1996b). A number of specific cleavage products including p49 (MA-CA-p2-NC), 
p41 (MA-CA), p25 (CA-p2) and p24 (CA) have been observed in cell lysates and culture 
supernatants from insect cells expressing PrSSgag(Wagner et al., 1992) or chimaeric Gag proteins 
(Tobin et al., 1996a). This processing is normally partial, and the full-length proteins can still be 
detected by western blot. The presence of p41 in the culture supernatant has also been attributed 
in part to a premature translational stop signal near the C-terminus of CA (Gowda et aI., 1989). 
Degradation of Pr5Sgag VLPs in the culture medium also occurs, and this has been linked to cell 
lysis which releases proteolytic enzymes (Cruz et aI., 1999). In most cases this VLP particle 
degradation can be minimized by process optimization. 
3.1.3 Bac-to-Bac® Baculovirus Expression System 
In this study, the Bac-to-Bac® Baculovirus Expression System (A.S) was chosen to express Gag-
based proteins in insect cells. The recombinant Gag donor vectors described in Chapter 2 were 
used to generate the corresponding rAcNPV. A quantitative comparison of protein expression 
levels in this system requires the standardization of the multiplicity of infection (MOl), where 
infections are conducted at a defined virus:cell ratio. A prerequisite to this is the accurate 
determination of the viral titre of amplified rAcNPV stocks by plaque assays, where the numbers 
of plaque forming units in serial dilutions of rAcNPV stock are counted in monolayer infections. 
3.1.4 Chapter aims 
The main aims of the work reported in this chapter were to: 
1. Generate rAcNPV from the 17 Gag donor vectors described in Chapter 2. 
2. Determine whether the expected Gag and Gag fusion proteins (Fig. 2.10) are expressed in 
rAcNPV infected insect cells and whether the same proteins are present in the culture 
supernatant, using western blot analysis. 
3. Investigate whether the chima eric Gag proteins are localized at the cell membrane using 
indirect immunofluorescence. 
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3.2 MATERIALS AND METHODS 
3.2.1 Insect cell culture. 
The Spodoptera frugiperda cell lines, Sf9 and Sf21, and the Trichoplusia ni cell line High Five ™ 
(Invitrogen) were maintained in sterile tissue culture wells or flasks as recommended by the 
supplier. For infection with rAcNPV, Sf9 and Sf21 cells were grown in monolayer culture at 
2rC in TC-100 Insect medium (Sigma) supplemented with: 10% (v/v) foetal bovine serum 
(FBS, containing up to 50 mg/ml serum proteins, Gibco), 50 Itg/mt neomycin, 69.2 Itg/ml 
penicillin G and, 100 Itg/ml streptomycin. For expression of proteins in serum-free medium, High 
Five ™ cells were grown in Express Five® medium (Gibco) with 10 Itg/ml gentamycin and 
18 mM L-glutamine. 
3.2.2 Generation of recombinant baculovirus. 
Recombinant baculoviruses were generated using the Bac-to-Bac® Baculovirus Expression 
System (Invitrogen, A.S). Briefly, recombinant pFastBac™Dual constructs were used 
individually to transform competent Escherichia coli DH1 OBac ™ cells (Invitrogen) by standard 
heat shock transformation (Sambrook et aI., 2001) to allow transposition of gag and chimaeric 
gag DNA constructs into the resident bacmid. The recombinant bacmid DNA was extracted by a 
modified alkaline lysis method according to the Bac-to-Bac® protocol. 
Sf21 cells (1 x 106) were seeded in 2 m} supplemented medium (3.2.1) into sterile 35 mm tissue 
culture wells and transfected with 10 Itl of a 1: 1 ratio of recombinant bacmid mini-prep DNA and 
Cellfectin™ (Invitrogen) according to the Bac-to-Bac® protocol. The rAcNPV stocks were 
amplified in 10m} volumes over 3 passages (according to the Bac-to-Bac® protocol), stored at 
4
c
C, and subsequently used to infect Sf9, Sf21 and High Five™ cells for protein expression in 
monolayer culture. 
3.2.3 Plaque assays. 
Sf9 cells (1.5 x 106) were seeded in 2 ml supplemented medium (3.2.1) into sterile 35 mm tissue 
culture wells and allowed to attach for 1 hr with gentle horizontal agitation (to ensure an even 
monolayer, confirmed by microscopy). The culture medium was removed and cells were infected 
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After a 2 hr incubation period at 2TC, infectant was removed and cells were overlaid with 3 ml 
Plaquing mix (Graces Insect Plaquing medium (Gibco), 4% SeaPlaque Agarose (Adcock Ingram) 
and water in a 2:1:1 ratio). Cells were stained 4 days post infection (dpi) with 100 JLg/ml Neutral 
red dye (Sigma) for 5 hr, and incubated for another day at 2TC before plaques were counted. 
3.2.4 Protein samples and SDS-PAGE. 
Sf21 and High Five ™ cells (1 x 106) were seeded in 2 ml supplemented medium (3.2.1) in 35 mm 
tissue culture wells, infected with 20JLl rAcNPV stock and protein samples were collected at 3 
dpi. Infected culture supernatant was removed from the tissue culture well, cleared by 
centrifugation at 2600 x g in a benchtop centrifuge for 10 min and diluted in a quarter volume of 
5x sample loading buffer (A.2). The infected monolayer cells were washed twice in 1 ml 
phosphate buffered saline (PBS, A.2) and resuspended in 1 ml PBS. Cells were lysed by the 
addition of loading buffer and heating at 90°C for 5 min, as reported previously (Luo et aI., 
1992). The samples were then either stored at -20'C for later use or separated by sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) using 10% denaturing gels (Sambrook 
et al., 2001). The positive control proteins used in SDS-PAGE are listed in Table 3.1, and a pre-
stained molecular weight (MW) marker (PageRuler™, Fermentas) was used on all blots. 
3.2.5 Western blotting. 
For western blotting, proteins were transferred from the SDS-PAGE gels onto nitrocellulose 
membranes (NitroBind, Osmonics Inc.) in transfer buffer (A.2) using a Trans Blot® semi-dry 
transfer cell (Bio-Rad) at 15 V for 2 hr. Membranes were then pre-incubated in blocking buffer 
(A.2) overnight and probed with appropriate primary antibodies (Table 3.2) for 2 hr in blocking 
buffer at ambient temperature. Following 3 sets of washes in washing buffer (A.2) for 10 min 
each, blots were hybridised with the appropriate secondary antibody (Table 3.3) for 1 hr in 
blocking buffer at ambient temperature. After a second set of washes, blots were developed with 
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TABLE 3.1. Positive control proteins used in SOS-PAGE and western blotting 
I Protein Details Size (kDa) Designation 
HIV -\ BH 10 Pr55 gag 55 303058 
HIV -1 HXB2 Reverse Transcriptase dimer (E. coli) 51,66 2897 
Jef Recombinant HIV -I Nef (E.coli) 27 EVA650 
1 Quality Biological, Inc, Gaithersburg, USA. 
NIH AIDS Research & Reference Reagent Program, McKesson BioServices Corporation, 
Germantown, USA. 
National Institute for Biological Standards and Control (NIBSC), Centralised Facility for 
AIDS Reagents, Medical Research Council (MRC), United Kingdom (UK). 
TABLE 3.2. Primary antibodies used in western blotting 
Antigen Host Dilution Details Designation 
p24 Rabbit \ :2000 
Polyclonal antiserum to recombinant 
ARP432 
HIV-\ HXB2 p24 GST (E.coli). 
p24 Mouse \:500 
Monoclonal antibody to HIV -I p24/p55. 
ARP319 
Mapped to RMYSPT 
RT Sheep 1:2000 
Polyclonal antiserum to Recombinant 
ARP428 
HIV-I LA V Reverse Transcriptase 
I Nef Mouse 1:1000 
Monoclonal antibody (lgG I) to HIV -I t\ef. 
01-003 
Mapped to VEEANK 
SV5-Pk Mouse 1:1000 
Monoclonal antibody to the SV5-Pk tag. 
EVA3066 
Mapped to IPNPLLGLD 
I National Institute for Biological Standards and Control (NIBSC), Centralised Facility for 
AIDS Reagents, Medical Research Couneil (MRC), United Kingdom (UK). 
FIT Biotech Oyj Pic, Tampere Finland. 
TABLE 3.3. Secondary antibodies used in western blotting 
Antigen Host Dilution Details 
Rabbit IgG Goat 1 :5000 Affinity purified alkaline phosphatase conjugate 
Sheep (gG Goat 1:5000 Affinity purified alkaline phosphatase conjugate 
Mouse [gG Goat 1:5000 Affinity purified alkaline phosphatase conjugate 
I Sigma, AtIasville, South Africa 
Source 
Commercial 1 
S. Le Grice 2 
V. 
Source 
G. Reid 1 
L Maaheim 1 
M. Page 1 
FIT Biotech 2 
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3.2.6 Indirect immunofluorescence (II F) 
Sf21 cells (1 x 106) were seeded in 2 ml supplemented medium (3.2.1) onto sterile 400 mm2 glass 
cover slips in 35 mm tissue culture wells, left to settle for 30 mins, and infected with 20 Itl 
recombinant baculovirus stock. At 3 dpi, cells were fixed and permeabilised in situ with 100% 
methanol at -20'C for 20 min. The rest of the procedure was conducted at ambient temperature. 
Cover slips were washed (3 times for 10 min each) in PBS-IIF (A.2) and then incubated in 
blocking buffer (A.2) for 2 hr. After washing, cover slips were probed with the appropriate 
primary antibody (Table 3.4) in blocking buffer for 3 hr. Following 3 more washes (PBS-IIF), 
cover slips were reacted in the dark with fluorescein isothiocyanate (FITC) conjugated anti-
mouse IgG (l :500, Sigma) in blocking buffer for 1 hr, and washed. Nuclei and cell membranes 
were stained for 1 hr in the dark with 5 Itg/ml 4,6-diamidino-2-phenylindole (DAPI, Sigma) and 
0.01 % Evans Blue (BDH Chemicals Ltd.) in wash buffer respectively, with washing in between. 
Cover slips were then mounted on glass slides in Gel Mount™ (Sigma), sealed, and stored in the 
dark at 4°C. Cellular fluorescence was viewed with a Zeiss AxioVert 200M fluorescent light 
microscope (Faculty of Health Sciences, University of Cape Town). Photographs were obtained 
using a Zeiss AxioCam MRm digital camera and Axio Vision 4.0 software. 
TABLE 3.4. Primary antibodies used in IIF 
Antigen Host Dilution Details Designation 
RT Mouse J :500 
Monoclonal antibody to HIV-J RT. Mapped 
EVA3018 
to PLTEEAELELAENREILKEPVHGVY 
l"ef Mouse 1:500 
Monoclonal antibody (lgG 1) to HIV-J Nef. 01-003 
Mapped to VEEANK 
SV5 Mouse 1:500 
Monoclonal antibody to the SV5-Pk tag. 
EVA3066 
Mapped to IPNPLLGLD 
I National Institute for Biological Standards and Control (NIBSC), Centralised Facility for 
AIDS Reagents, Medical Research Council (MRC), United Kingdom (UK). 
FIT Biotech Oyj Pic, Tampere Finland. 
Source 
D. Helland and 
A. Szilvay I 
FIT Biotech 2 
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3.3 RESULTS 
3.3.1 Plaque assays. 
Plaque assays were used to determine the viral titre of rAcNPV stocks in the Bac-to-Bac® 
Baculovirus Expression System (A.S). The protocol was optimized as far as possible, and plaque 
counts from individual assays were made. However, in replicate assays at the same dilution, the 
number of plaques would often vary by more than 50-fold. For example, plaque counts from 
equal volumes of a 10-5 dilution of rAc-WTgagC stock would range from less than 5 to more than 
250. Similar counts were recorded for rAc-HMgagC stocks. All attempts to develop a 
reproducible plaque assay were unsuccessful. 
In the absence of accurate rAcNPV stock titres, the MOl could not be standardized in 
experimental sets. Therefore, quantitative analysis of protein expression between different 
constructs was not completed. To facilitate at least semi-quantitative comparisons, experimental 
sets of infections were standardized as much as possible. Essentially, equal volumes of bacmid 
DNA preparations were used in all the initial transfections and subsequent viral amplifications 
were conducted uniformly using the same insect cell starter cultures. An equal volume of each 
rAcNPV stock was then used for each infection within a single set of experiments. 
3.3.2 Western blot analysis 
Initially, all Gag-based constructs were expressed in Sf21 cell monolayers. However, the high 
concentration of serum proteins present in the medium obscured protein bands in the ~50-75 kDa 
range on western blots of culture supernatant samples. Therefore, all Gag-based constructs were 
also expressed in High Five™ cell monolayers adapted to serum-free medium. This circumvented 
the problem of serum proteins in the culture supernatant samples, but protein yields were 
consistently lower compared to Sf21 cells (as estimated from band intensity on western blot). 
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3.3.2.1 Gag control constructs 
The five Gag control constructs (Fig. 2.10) each expressed an intracellular protein of the expected 
size (50 or 55 kDa) in Sf21 cells, which reacted with p24-specific antiserum (Fig. 3.1). There was 
no substantial difference in WTgagC and HMgagC band intensity, and analogous blots from 
infected High Five ™ cells were comparable (data not shown). Expression of the four humanized 
Gag control constructs in High Five ™ cells allowed for culture supernatant proteins to be 
observed (Fig. 3.2). As expected, bands in the culture supernatant corresponding to HMgagC and 
THMgagC reacted strongly with p24-specific antiserum. Although the H~MgagC and 
TH~MgagC bands in the culture supernatant were less intense than the corresponding Myr+ 
analogues, they were still detectable with p24-specific antiserum (Fig. 3.2). Bands in the 
expected positions for p41 and p25/24 were evident in the culture supernatant for each Gag 
control construct (Fig. 3.2). Since bands at the expected p25 and p24 positions were not always 
clearly distinguishable, they are indicated here as p24 only. 
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FIGURE 3.1. Expression of control Gag proteins in Sf21 cells. 
Sf21 cells were infected with AcNPV (baculovirus) or rAcNPV expressing one of the 5 Gag control 
proteins indicated. Cells were harvested at 3 dpi and 10 III of cell lysate was loaded in each lane. 
Membranes were probed with p24-specific antiserum, +Gag = 50 ng. Arrowheads indicate the full-
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FIGURF 3.2. Comparison of Myr+ and Myr- Gag expression in High Five™ cell Iysates and culture 
supernatants. High Five™ cells were infected with rAcNPV expressing one of the 4 control Gag proteins 
indicated. Cells were harvested at 3 dpi and 10 t.Ll of cell lysate (Ly) or 30 JLI culture supernatant (Sn) was 
loaded in each lane. Membranes were probed with p24-specific antiserum. Arrowheads indicate the full-
length and p6-truncated Gag protein bands. Arrows indicate supernatant bands corresponding to p41 and 
p24 positions. M = MW marker. 
3.3.2.2 RTTN-derived constructs 
Celllysates 
52 
Each of the 10 RTTN-derived chimaeric constructs (Fig. 2.10) expressed a full-length 
intracellular protein of the expected size that was detected with p24-specific antiserum 
(Fig. 3.3A, B) and anti-p24 mAb (Fig. 3.4A, B) in High Five™ and Sf21 cells. A number of 
other bands were detected with p24-specific antiserum, but for the fusions containing TN 
moieties (-3'TN, -TN and -RTTN) there were I or 2 prominent bands (Fig. 3.3A, B). Those in 
-3TN and -RTTN fusions were also detectable with anti-p24 mAb (Fig. 3.4A, B). Detection with 
RT-specific antiserum confirmed that HMgag and THMgag-fusions with -3'RT, -RT and -RTTN 
carried RT protein (Fig. 3.5A). Similarly, probing with anti-Nef mAb (mapped to the C-terminal 
half of Net) demonstrated that all fusions with -3 'TN, -TN and -RTTN carried Nef protein 
(Fig. 3.5B). As Nef is C-terminal to the shuffled Tat in -TN and -RTTN fusions, the presence of 
Tat in these constructs was inferred from the positive reaction of the anti-Nef mAb with the TN-
containing Gag fusion proteins, together with protein band sizing by western blot. The prominent 
Gag containing bands of lower MW for fusions with TN moieties (Fig. 3.3A,B & 3.4A,B) were 
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FIGURE 3.3 . Expression of RTTN-derived chimaeric Gag proteins in insect cell Iysates and culture supernatants. 
High Five™ (panels A-D) and Sf21 (panels E, F) cells were infected with rAcNPV expressing one of 10 RTTN-derived 
chimaeric Gag proteins . Cells were harvested at 3 dpi and 10 /11 of cell lysate (Ly) or 30 /11 of culture supernatant (Sn) was 
loaded in each lane. Membranes were probed with p24-specific antiserum, +Gag ~ 100 ng. Arrowheads indicate the full-
length chimaeric Gag protein bands; dots indicate distinct bands of lower MW. Arrows indicate supernatant bands 
corresponding to p41 and p24. The blotting disruption due to serum proteins is indicated for Sf2 I supernatants. 
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FIGURE 3.4. Detection of RTTN-derived chimaeric Gag proteins in insect cell Iysates with anti-
p24 mAb. High Five™ (A) and Sf21 (B) cells were infected with rAcNPV expressing one of the 10 
RTTN-derived chimaeric Gag proteins. Cells were harvested at 3 dpi and 30 J.l.1 of cell lysate was loaded 
in each lane. Membranes were probed with anti-p24 mAb, +Gag = 100 ng. Arrowheads indicate the 
full-length chimaeric Gag protein bands. M = MW marker. 
Culture supernatant 
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In High Five ™ cells, all RTTN-derived chimaeras (except -RTTN fusions) were detected in the 
culture supernatant with p24-specific antiserum (Fig. 3.3C, D), although the -RT fusion bands 
were only just visible (Fig. 3.3D). In Sf21 cells, 7 of the 10 RTTN-derived chimaeric proteins 
were detected in the culture supernatant with p24-specific antiserum (Fig. 3.3E, F). 
The three that could not be detected (HMgag3'RT, THMgag3'RT and THMgag3'TN) as well as 
the prominent bands of lower MW for the fusions with TN moieties are within the MW range that 
was obscured by the medium serum proteins. The cleavage products p41, and to a lesser extent 
p24, were also evident in culture supernatants. For both cell lines, the intensity of the chimaeric 
protein bands relative to p41 appears to decrease with an increase in MW of the protein chimaera 
(e.g. Fig. 3.3F). Under improved expression conditions, that were not part of these controlled 
experimental sets, culture supernatant levels of Sf2l expressed -RTTN fusions were higher than 
those presented in Figure 3.3F, as estimated from band intensity (data not shown). 
Four of the culture supernatant samples from Sf21 cells (Fig. 3.3C) and 6 from High Five ™ cells 
(Fig. 3.3F) were also run on gels with the corresponding celllysates in adjacent lanes, confirming 
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FIGURE 3.5. Detection of RTTN-derived chimaeric Gag proteins in High FiveT\1 cells with anti-
RT antiserum and anti-Nef mAb. High Five™ cells were infected with rAcNPY expressing one of 10 
RTTN-derived chimaeric Gag proteins. Cells were harvested at 3 dpi and 10 J.d (A) or 30 Jll (8) of cell 
lysate was loaded in each lane. Membranes were probed with RT-specific antiserum (A) and anti-Nef 
mAb (8). Control proteins: +RT (100 ng) is a heterodimer, +Nef (50 ng) is partly present as a 
homodimer (- 50 kDa) . Arrowheads indicate the full-length chimaeric Gag protein bands. 
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3.3 .2.3 Gag-PE constructs 
Cell lysates 
56 
Both Gag-PE constructs expressed an intracellular protein of the expected MW that was detected 
with p24-specific antiserum (Fig. 3.6A). These Gag-PE proteins each carry the SV5 murine mAb 
epitope (IPNPLLGLD) on their C-termini, and reactivity with anti-SV5-Pk rnAb confirmed that 
these fusions contained full-length PE (Fig. 3.6B). 
Culture supernatants 
Unlike the shortest two RTTN-derived fusions (Gag-3'RT and Gag-3'TN, Fig. 3.3C), the Gag-PE 
proteins could not be detected in High Five™ cell culture supernatant with p24-specific 
antiserum (Fig. 3.6C), but p41 and p24 bands were visible. Gag-PE proteins were not detectable 
in Sf21 cell culture supernatants (data not shown), but these proteins are within the MW range 
that is obscured on western blots by serum proteins in the culture medium . 
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FIGURE 3.6. Expression of Gag-PE proteins in High Five™ celilysates and supernatants. 
High Five™ cells were infected with rAcNPV expressing one of the Gag-PE proteins. Cells were 
harvested at 3 dpi and 10 ttl (A), 5 III (8) of cell lysate (Ly) or 30 III culture supernatant (Sn) was loaded 
in each lane. Membranes were probed with p24-specific antiserum CA, C), and anti-SV5-Pk mAb (8). 
Arrowheads indicate the full-length chimaeric Gag protein bands. Arrows indicate supernatant bands 
corresponding to p41 and p24. Controls: +Gag and baculovirus (Ly) reactivity with p24-specitic 
antiserum as for Figure 3.3. The SV5-Pk tag (IPNPLLGLD) is located at the C-terminus of the Gag-PE 
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3.3.3 Indirect immunofluorescence 
The cellular localization of Gag-based proteins m Sf2l cells was investigated by indirect 
immunofluorescence (IIF), to ascertain whether these proteins were localized at the cell 
membrane. 
3.3.3.1 Gag control constructs 
Cells infected with one of the 4 humanized Gag control constructs (HMgagC, THMgagC, 
Ht-.MgagC and THt-.MgagC) or an AcNPV negative control were probed 3 dpi with one of 5 
different Gag antibodies (E.l) and a suitable fluorescent conjugate. In each case IIF staining was 
either absent or non-specific (E. I ). 
3.3.3.2 RTTN-derived constructs 
With the exception of the -3'RT fusions, all RTTN-derived protein chimeras were visualized in 
Sf21 cells by JIF staining of the fusion component within the chimaeric protein (Fig. 3.7-3.9). 
The Gag-3'RT constructs contain the C-terminal 113 aa of RT, and an anti-RT mAb (ARP384, 
E.l) mapped to the C-terminal 100 aa of RT was available. Although Gag-3'RT and Gag-RT 
were detected with ARP384 by western blot, IIF staining was absent in cells expressing these 
proteins that were probed with ARP384 (data not shown). Anti-Nef mAb was used to detect -
3'TN (Fig. 3.7A, B). -TN (Fig. 3.8A, B) and -RTTN (Fig. 3.8C, D) fusions. while anti-RT mAb 
(EVA3018, 3.2.6) was used to detect Gag-RT (Fig. 3.9A, B). For each construct, proteins could 
be detected in the cytoplasm within some cells (e.g. Fig. 3.9A), and DAPI staining of cell nuclei 
(data not shown) confirmed these proteins were external to the nucleus. However, in all cells that 
showed IIF staining (including those with additionallIF staining in the cytoplasm), proteins were 
detected as a distinct layer (Fig. 3.7-3.9, white arrowheads) or in concentrated sections 
(e.g. Fig. 3.8C) at the cell periphery. Staining of cellular membranes with Evans Blue dye 
confirmed that this green fluorescent layer was not within the cytoplasm, and provides evidence 
for the co-localization of these proteins with the cell membrane itself. In addition, patches of 
protein localized to the exterior cell surface were visualized at appropriate focal planes 
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FIGURE 3.7. Evidence for the localization of Gag-3'TN chimaeras to the Sf21 ceU membrane. 
Sf21 cells infected with rAcNPV (expressing the indicated proteins) were labeled with anti-Nef mAb 
and detected with secondary FITC-conjugated anti-mouse IgG I (green fluorescence). Cellular 
membranes were stained with Evans Blue dye (red fluorescence) and the images were merged in the 
overlay panels. Negative control: rAc-HMgagC infected cells. White arrowheads indicate IIF staining at 
the cell membrane while the yellow arrowhead indicates an example of isolated fluorescent IIF staining 
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FIGURE 3.8. Evidence for the localization of Gag-TN and Gag-RTTN chimaeras to the Sf2l cell 
membrane. Sf21 cells infected with rAcNPV (expressing the indicated proteins) were labeled with 
anti-Nef mAb and detected with secondary FITC-conjugated anti-mouse IgG I (green fluorescence). 
Cellular membranes were stained with Evans Blue dye (red fluorescence) and the images were merged 
in the overlay panels. Negative control (rAc-HMgagC infected cells) as for Figure 3.7. White 
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FIGURE 3.9. Evidence for the localization of Gag-RT chimaeras to the Sf21 cell membrane. 
Sf21 cells infected with rAcNPV (expressing the indicated proteins) were labeled with anti-RT mAb 
and detected with secondary FITC-conjugated anti-mouse IgG (green fluorescence). Cellular 
membranes were stained with Evans Blue dye (red fluorescence) and the images were merged in the 
overlay panels. Negative control: rAc-HMgagC infected cells. White arrowheads indicate IIF staining 
at the cell membrane while the yellow arrowhead shows an example of isolated fluorescent IIF 
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3.3.3.3 Gag-PE constructs 
The Gag-PE proteins were detected in Sf2l cells probed with anti-SV5-Pk mAb by IIF staining 
(Fig. 3.1 OA, B). In both cases, protein was detected throughout the cytoplasm, but not in the 
nucleus (no co-localization of IIF staining with DAPI stained nuclei, data not shown). In contrast 
to the RTTN-derived Gag chimaeras, no distinct protein concentration was visible at the cell 
periphery. However, since the IIF staining of the cytoplasmic proteins extended completely to the 
cell boundary, some membrane localization could have occurred. However, these data were 
inconclusive in demonstrating membrane localization ofGag-PE chimaeras. 




FIGURE 3.10. Localization of Gag-PE chimaeras within Sf2l cells. 
Sf2l cells infected with rAcNPV (expressing the indicated Gag-PE fusions) were labeled with anti-
SV5-Pk mAb and detected with secondary FITC-conjugated anti-mouse IgG (green fluorescence). 
Cellular membranes were stained with Evans Blue dye (red fluorescence) and the images were merged 
in the overlay panels. Negative control: rAc-HMgagC infected cells. Bar = 20 11m, all photographs at 
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3.4 DISCUSSION 
In an attempt to determine the viral titre of each rAcNPV stock, plaque assays were conducted. 
Plaque counts from rAc-WTgagC and rAc-HMgagC stocks indicated that accurate titre 
determinations could not be obtained with this method under the conditions used, and 
consequently the MOl could not be set. Although infection conditions were standardized as far as 
possible (3.3.1), without a standardized MOl the differences in protein expression could not be 
quantified. Therefore, any change in Gag expression level due to human codon optimization, 
myristylation, p6-truncation or the fusion component could not be evaluated. To conduct such 
studies on protein expression in the future, either a reproducible plaque assay for our group's 
laboratory conditions will need to be developed, or another method to titre baculoviral stock 
(e.g. TCIDso assay) will need to be pursued. However, the main objectives of this section of the 
study were to confirm expression of the correct proteins, determine whether full-length chimaeric 
proteins were present in the culture supernatant and examine intracellular protein localization. 
N one of these analyses were precluded by the infection conditions used, and the relative levels of 
intra- and extracellular proteins for each construct could still be observed by western blot. 
There was an obvious difference in protein composition between cell lysate and culture 
supernatant for each of the four humanized Gag controls (Fig. 3.2). This indicated that the full-
length proteins (50 or 55 kDa), p41 and p24 were not present in the culture supernatant due to 
cell lysis alone. Precursor proteins may be released from the cell and then partly cleaved into p41, 
p24 and other breakdown products, or this partial cleavage may occur intracellularly prior to 
protein release. These explanations are not mutually exclusive and evidence in the literature 
(Wagner et al., 1992; Cruz et al., 1999) suggests that both processes do occur. The predominance 
of Myr+ Gag (HMgagC and THMgagC) in the culture supernatant (relative to p41 and p24) 
compared to Myr- Gag (HL\MgagC and THL\MgagC) may be explained by the finding that Myr+ 
Gag is released from rAcNPV infected insect cells as VLPs and soluble protein, whereas Myr-
Gag is only released in the soluble form (Royer et aI., 1992), but this would require further 
investigation. 
The expression of each of the 10 RTTN-derived Gag chimaeras (Fig. 2.10) was confirmed by 
western blot of cell lysates, where a band of the expected MW was detected with p24-specific 
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Celllysates of cells expressing fusions containing TN moieties (-YIN, -TN and -RITN) had I or 
2 distinct bands oflower MW (Fig. 3.3A, B). Since these bands did not react with anti-Nef mAb 
(Fig. 3.5B), these products may have resulted from specific proteolytic cleavage within the TN 
moiety, or from premature termination of translation at a defined point in the C-terminal fusion. 
Each RTTN-derived Gag chimaera was shown to be present in the culture supernatant (for one or 
both cell types), and for the same reasons as for the Gag controls, these proteins were probably 
selectively released from the cell. It appears that smaller fusions may be released more 
efficiently. For example, the difference in band intensity for HMgag3 'RT between the cell lysate 
and culture supernatant (Fig. 3.3A, C) is qualitatively less than for HMgagRT (Fig. 3.3B, D). 
Alternatively, larger fusions may be degraded at a higher rate in the culture supernatant. \Vhen 
p41 is expressed alone, it is efficiently released from insect cells (Royer et af., 1992), therefore 
the p41 present in the culture supernatant (Fig. 3.2 & 3.3C-F) may originate from intra- or 
extracellular cleavage of chimaera Gag precursors, or from a premature translation stop signal 
(3.1). Chimaeras with longer fusions showed qualitatively less full-length chimaera relative to 
p41 in the culture supernatant than shorter fusions (e.g. compare HMgagTN and HMgagRTTN 
lanes, Fig. 3.3F). However, from these data it is not clear whether these differences were as a 
result of lower synthesis, lower release or higher cleavage levels of the larger fusion proteins. 
Unlike the RTTN-derived chimaeras, neither of the Gag-PE constructs was detected in the culture 
supernatant with p24-specific antiserum (Fig. 3.6B). Either the -PE fusions were not released 
from the cell, or the levels were below the detection limit. Complete degradation of HMgagPE or 
THMgagPE in the culture supernatant is unlikely since p41 had not been fully processed. 
The cellular localization of Gag control proteins could not be visualized by IIF with the five anti-
Gag antibodies available in this study. Therefore, the localization of chimaeric Gag proteins 
within the cell was evaluated without comparison to positive controls for membrane localization 
(HMgagC and THMgagC). As such, the distinct protein layers (or concentrations) at the cell 
periphery for the -3 'TN, -TN, -RT and -RTTN fusions must be regarded as supportive rather than 
direct evidence for membrane localization. Moreover, the distinct patches of protein detected on 
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a comparative IIF stained positive VLP control. No results were obtained for IIF staining of -
3 'RT fusions, but the available mAb (ARP384) to this portion of RT was unable to show IIF 
staining of cells expressing -RT fusions either. Since both -3'RT and -RT fusions were detected 
by ARP384 in western blot, the epitope recognized by the mAb is probably not accessible to 
antibody binding in the native chima eric proteins. IIF staining results for cells expressing -PE 
fusions were inconclusive regarding membrane localization, but the even distribution of Gag-PE 
chimaeras in the cytoplasm suggested that even if membrane targeting did occur for these 
proteins, it was not efficient. 
The movement of RTTN-derived fusion proteins into the culture supernatant, in conjunction with 
the apparent localization of these chimaeras to the cell membrane (not demonstrated for the -
3'RT fusions), provided supportive evidence for VLP formation. Yet the release of these 
constructs from the cell as soluble proteins, or as other budding structures via the cell membrane 
cannot be excluded. 
Based on the available literature on tolerable fusion size, VLP formation from the -3 'RT, -PE and 
-3 'TN constructs could reasonably be expected, but not for -TN, -RT and -RTTN fusions 
(Deml et al., 2005). Therefore, only the 6 smallest chimaeric Gag constructs (Fig. 2.10) would be 
expected to be readily detectable at high levels in the culture supernatant. The results presented 
here are in contrast to this prediction, and supported further investigation of all 10 RTTN -derived 
constructs for VLP production. Given the anticipated immunogenicity of the Gag-PE chimaeras, 
and their unexpected expression properties described here, these constructs also warranted further 
characterization, to clarify why these chimaeras displayed different expression patterns compared 
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4.1 INTRODUCTION 
The potential use of Gag and chimaeric Gag VLPs as candidate HIV vaccines has led to the 
refinement of protocols to pmify these particles from heterologous expression systems for 
biochemical and immunological analysis. VLPs produced in the baculovirus expression system 
are typically harvested from clarified culture supernatant by ultracentrifugation through a sucrose 
density gradient ranging from between 10% and 70% in PBS. Preparations of VLPs by these 
methods are stable and generally have a purity of greater than 80% (Oem) et al., 200S; Ooan et 
af., 2005). VLP identity, composition and morphology are typically investigated by western 
blotting and electron microscopy, and these techniques are suitable for determining whether 
chimaeric Gag proteins form type I VLPs. 
4.1.1 Sucrose density gradient centrifugation 
PrSSgag VLPs have a sedimentation coefficient of ~600S (Svedberg units) in sucrose density 
gradients (Royer et aI., 1992) and a density of 1.1S-1.20 glml (Wagner et al., 1992). Type I 
chimaeric Gag-V3 and Gag-C04BO VLPs also have densities in this range (Wagner et al., 
1996b; Wagner et al., 1994a). Sucrose sedimentation analysis has shown that fractions in the 
gradient with the highest p24 content (antigenic peaks) overlap with the fractions containing 
Pr55gag VLPs (Wagner et aI., 1992). The particle-containing fractions generally correspond to the 
~40-50% sucrose region of the gradient, and the Gag particle band in this region can be 
visualized by white-light trans-illumination. Soluble proteins such as p41 and serum proteins in 
the culture medium have much lower sedimentation coefficients, and remain at the top of the 
gradient (Royer et al., 1992). A disadvantage of these sucrose density gradient centrifugation 
strategies is that baculovirus cannot be completely separated from the VLPs produced in the 
baculovirus system. Although this is undesirable for clinical VLP preparations, these 
contaminating baculoviruses have been implicated in enhancing immune responses by acting as 
danger signals to stimulate the innate immune system (1.4.2). 
4.1.2 Transmission electron microscopy (TEM) 
The two broad applications of TEM in this context are to visualize particles in VLP preparations 
and to examine budding and internal VLP structure in ultrathin sections. Pr5Sgag VLPs produced 
by rAcNPV in insect cells were indistinguishable from those produced in mammalian cells by 
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(Gheysen et al., 1989; Jaffray et ai., 2004). Larger particles (160 nm) and oligomeric structures 
resulting from incompletely dissociated complexes or fused particles were also evident (Wagner 
et al., 1992). Type I VLPs have shown larger particles with less homogenous morphology 
(1.6.3.2). Immunoelectron microscopy (IEM) has been used to confirm the presence of Gag and 
fusion components within type I in-frame VLPs by immunogold labeling of ultrathin sections. 
4.1.3 Chapter aims 
To ascertain which chimaeric Gag constructs formed VLPs, the main aims of the work reported 
in this chapter were to: 
1. Perform sucrose density gradient centrifugation analysis on the culture supernatant of 
rAcNPV infected insect cells to partly purify any VLPs or budded particles produced. 
2. Analyze the protein content of the VLP preparations by western blot and characterize any 
VLPs present in the preparations by TEM. 
3. Analyze the budding and internal ultrastructure ofVLPs in ultrathin sections by TEM. 
4. Confirm the presence of the fusion components of the chimaeric Gag proteins within VLPs 
by IEM. 
4.2 MATERIALS AND METHODS 
4.2.1 Insect cell culture 
Sf21 cells were cultured as a monolayer in supplemented medium (3.2.1) and 10 ml volumes 
were infected with 100 III rAcNPV stock. For suspension culture of Sf9 cells, 500 ml glass flasks 
were prepared by coating with Repe1cote (VWR International Ltd), washing, autoclaving and 
baking at 200°C for 2 hr. Sf9 cells were grown in supplemented medium with the addition of 
0.1 % Pluronic® F-68 (a surfactant to decrease membrane shearing in suspension culture, Sigma). 
Culture flasks were incubated at 2TC in a rotary shaker at 120 rpm. 
4.2.2 Budded particle purification methods 
4.2.2.1 Sucrose cushion centrifugation (Seq 
Culture supernatant (20 ml) from pooled Sf21 monolayer infections was collected 3 dpi and 
cleared by centrifugation at 3800 x g in a Beckman JA-14 rotor for 10 min at 25°C. Clarified 
supernatant was layered onto a sucrose cushion (7 ml 30% sucrose above 2 ml 70% sucrose in 
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for 90 min at 4°e. The particulate material at the interface between the sucrose concentrations 
was syringe-extracted (by side puncturing tube), resuspended in 10 ml PBS, and centrifuged at 
110000 x g for 30 min in a Beckman SW 55 Ti rotor at 4°e. Pelleted material was resuspended 
in 500 l.tI PBS with Complete Protease Inhibitor Cocktail'b' (Roche), and stored at -20°e. 
4.2.2.2 Sucrose cushion and density gradient centrifugation (SXC) 
Alternatively, particulate material in 40 m! infected Sf21 culture supernatant extracted from a 
sucrose cushion, was loaded onto a continuous 30-70% sucrose density gradient and centrifuged 
in a Beckman SW 28 rotor at 120000 x g for 90 min at 4°e. The particle-containing band was 
visualized and syringe-extracted under white-light trans-illumination and then pelleted as 
described (4.2.2.1). 
4.2.2.3 Sucrose density gradient centrifugation (SGC) 
Culture supernatant from 60ml Sf9 suspension culture infected with 600111 of rAcNPV stock was 
harvested at 3 dpi and cleared by centrifugation at 3800 x g in a Beckman JA-14 rotor for 10 min 
at 25°e. Clarified supernatant was centrifuged in a Beckman type 35 rotor at 105 000 x g for 3 hr 
at 4°C. The pellet was resuspended in 1 ml PBS and sedimented through a continuous 30-70% 
sucrose density gradient at 120 000 x g in a Beckman SW 28 rotor for 2 hr at 4°C. The VLP-
containing band was syringe-extracted under white-light trans-illumination, resuspended in 40 ml 
PBS, and re-centrifuged at 120 000 x g for 1 hr. Purified VLPs were resuspended in 500 III PBS 
with Complete Protease Inhibitor Cocktail:(:) (Roche), and stored at -20°e. 
4.2.3 Western blotting 
Samples from SCC, SXC and SGC preparations were diluted in 5x sample loading buffer (A.2), 
separated by SDS-PAGE and analyzed by western blot (3.2.5). 
4.2.4 Transmission electron microscopy (TEM) 
4.2.4.1 Adsorbed particle TEM CapTEM) 
SCC, SXC and SGC sample preparations were adsorbed onto carbon coated copper grids for 20 
min at ambient temperature, rinsed twice in distilled, de-ionized water (ddH20) and stained with 
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4.2.4.2 Thin section TEM (tsTEM) 
Sample preparation 
Sf21 cells (1 x 106) were seeded in 2 ml supplemented medium into 35 mm tissue culture wells 
and infected with 20111 rAcNPV stock. At 3 dpi cells were fixed overnight in situ with 2.5% (w/v) 
glutaraldehyde in PBS at 4°C in the dark. Fixed cells were gently resuspended in 1 ml PBS and 
pelleted at 2600 x g in a benchtop centrifuge, washed twice in PBS and resuspended in 2% (w/v) 
low melting point agarose in PBS at 37°C. Samples were post-fixed with 1% (w/v) osmium 
tetroxide in PBS, washed twice in PBS and twice in ddH20, dehydrated through an ethanol series 
(30, 50, 70, 80, 90, 95, 100%, 5 min each) and embedded in Spurr's resin (Spurr, 1969). Ultrathin 
sections, ~ 1 00 nm thick, were cut with a glass knife using a Leica Reichert Ultracuts microtome 
and mounted on copper grids. Sections were stained with 2% uranyl acetate for 10 min at ambient 
temperature, rinsed 5 times with ddH20 (1 min each), post-stained with Reynold's lead citrate 
(Reynolds, 1963) for 10 min, re-rinsed with ddl-hO and air dried. 
4.2.4.3 Immunoelectron microscopy OEM) 
Unstained ultrathin sections, mounted on duplicate Formvar-coated nickel grids, were floated 
section side downward on PBS containing 1 % (w/v) bovine serum albumen (BSA) for 5 min, 
then on PBS containing 0.02 M glycine for 3 min, and subsequently washed twice in PBS-BSA 
for 1 min. Duplicate grids were floated overnight at ambient temperature on p24-specific 
antiserum (Table 3.1, 1: 100 dilution in PBS-BSA), washed 5 times in PBS-BSA with 0.1 % (v/v) 
Tween 20 (PBS-BSA-T) and 3 times in PBS-BSA. Grids were then floated on anti-rabbit 
10 nm colloidal gold conjugate (Sigma, 1:50 dilution in PBS-BSA) for 2 h at ambient 
temperature and washed as above for primary antiserum. Conjugate labeled complexes were 
fixed in 1 % glutaraldehyde in PBS for 3 min, washed 5 times with ddH20, stained in 2% uranyl 
acetate for 10 min, washed 5 times with ddH20 and air dried. 
All apTEM, tsTEM and !EM samples were visualized with a LEO 912 transmission electron 
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4.3 RESULTS 
Two variations of a VLP purification strategy (Nennut et aI., 1994), SCC and SXC, were tested 
for the purification of Gag and chimaeric Gag particles expressed in rAcNPV infected insect 
cells. The resultant preparations were examined by western blot and apTEM, but results were 
inconclusive for VLP fonnation. Therefore, tsTEM and !EM were conducted, and larger scale 
VLP purifications were calTied out using SGc. 
4.3.1 Purifying particles from Sf21 culture supernatants 
4.3.1.1 SCC of Sf21 culture supernatant 
Initially a sucrose cushion was used to purify particles from 20 ml Sf21 culture supernatant. 
WTgagC and HMgagC SCC samples were comparable by western blot (Fig. 4.1 A), as expected 
from the cell lysate expression profiles (Fig 3.1). In THMgagC SCC samples there was a protein 
band of -115 kDa (that was not present in the culture supernatant) in addition to THMgagC 
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FIGURE 4. I. Control and chimaeric Gag proteins are detectable in some see samples. 
Sf21 cells were infected with rAcNPV expressing one of indicated constructs. Each lane was loaded 
with 25 I.ti of a SCC sample, where (A-D) represent blots from separate gels. Membranes were probed 
with p24-specific antiserum, +Gag = 50 ng. Arrowheads indicate the full-length Gag and chimaeric Gag 
protein bands. The arrow indicates a band of higher MW consistently present in THMgagC samples. 
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A band of the expected size was visible for the -YRT and -3 TN fusion proteins (Fig. 4.1 C & D), 
which was shown to be the same band present in the High Five™ culture supernatant (3.3.2.2) by 
comparison of samples run in adjacent lanes on the same gel (data not shown). In preparations 
where the protein yield was higher, such as the Gag-3 'TN examples shown (Fig. 4.1 D), there 
were an increased number of detectable bands, including p41 and p24. This may indicate 
preparations of lower purity or co-purification of soluble proteins. By this purification method, 
the -PE, -TI\T, -RT and -RTTI\T Gag chimaeras were not reproducibly detectable in see samples 
by western blot, and therefore sxe was investigated. 
4.3.1.2 sxe of Sfll culture supernatant 
In an effort to detect particles from -PE, -TN, -RT and -RTTN chimaeras, and improve 
preparation purity, the particulate material from 40 ml of culture supernatant extracted by see 
was then centrifuged through a 30-70% sucrose density gradient. The particle-containing band in 
the sucrose density gradient (e.g. Fig. 4.2A) was shown by western blot to contain chimaeric 


















FIGURE 4.2. SXC samples contain full-length proteins but not p41. 
(A) Example of a particulate band (THMgagC, SXC purification) in a sucrose gradient visible by white 
light trans-illumination (white arrowhead). (B) Particles were purified from culture supernatants of 
Sf21 cells expressing the indicated constructs, and 10 J.l1 of Sn or 25 J.l1 of SXC sample was loaded in 
each lane. The membrane was probed with p24-specific antiserum. Arrowheads indicate the full-length 
protein bands. The arrow indicates a band of higher molecular weight present in the THMgagC sample 
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These examples demonstrate that p41 in the culture supernatant is excluded from the particle 
purifications by SXC (compare p41 levels in Sn and SXC lanes, Fig. 4.2B). Gag-RT, Gag-RTTN 
and surprisingly Gag-PE constructs were only just detectable in SXC samples by western blot 
(data not shown). 
4.3.2 apTEM of SCC and SXC samples 
All see samples were analyzed by apTEM in an attempt to ascertain whether VLPs were present 
in the samples. The HMgagC and THMgagC samples (Fig. 4.3A, B) contained typical VLPs 
( 100-150 nm) based on previously characterized morphological features (Luo et aI., 1990; Jaffray 
el at., 2004). Structures resembling VLPs in overall morphology, were found in all chimaeric 
Gag see samples (e.g. 4.3C-E), but the size of these putative chimaeric VLPs ranged from 
150-300 nm. However, structures of very similar appearance could be found in the negative Gag 
control (AcNPV infection, Fig. 4.3F), and the negative VLP controls (Myr- Gag, data not 
shown), albeit at lower concentrations on the grid. Membrane-bound, folded baculovirus could be 
differentiated from Gag-only VLPs (compare 4.4A & B), but for the -PE, -RT and -RTTN 
SCC samples in particular, this distinction was not always clear since the putative VLPs were of 
similar size to the membrane-bound folded baculovirus (compare examples in Fig. 4.4C & 0). 
apTEM of SXC samples gave similar results for all constructs (data not shown). Essentially, 
apTEM was insufficiently objective under these conditions for conclusively determining if VLPs 
\\'ere present in sec and SXC samples. 
4.3.3 tsTEM 
The inadequacy of apTEM in this study for confinning VLP production (or characterizing the 
paliicles) prompted the use of tsTEM to analyze cells expressing chimaeric Gag proteins. It was 
reasoned that if budding of particles at the cell surface could be observed, this would be 
compelling evidence for the production of chimaeric Gag VLPs. In uninfected Sf21 cells, 
membrane protrusions (Fig. 4.SB) and cellular debris (Fig. 4.SC) were sometimes associated with 
the cell surface, but these were easily distinguished from Gag VLPs (compare to Fig. 1.2). 
Similar membrane protrusions were visible for AcNPV - and all rAcNPV -infected cells (data not 
shown). Single baculovirus particles were also visible budding from infected cells at the cell 
surface (Fig. 4.6A, inset). In these cases the internal rod-shaped virion is clearly identifiable, and 
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FIGURE 4.3. apTEM unable to confirm the presence of VLPs in see samples. 
Sf2l cells were infected with rAcNPV expressing one of the following constructs: HMgagC (A), 
THMgagC (B), HMgag3'RT (c), HMgag3'TN (D), HMgagPE (E), baculovirus (F). At 3 dpi SCP 
samples were prepared and analyzed by apTEM. I = VLP, identification based on distinctive 
morphology, II = co-purified baculovirus, III = membrane enclosed baculovirus (folded), IV = unknown 
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THMgagC 
THMgagPE 
FIGURE 4.4. Membrane bound, folded baculovirus could be misidentified as a large VLP by 
apTEM. Examples of structures in SCC samples with shared morphological features that could lead to 
misidentification. Representatives are shown from THMgagC (A, B) and THMgagPE (C, D) expressing 
cells. Arrowhead indicates a presumed baculovirus within a membrane. Bar = 100 nm, all micrographs 
at the same scale. 
NM CM 
FIGURE 4.5. Uninfected Sf21 cell morphology. 
(A) Sf21 cell not infected with baculovirus: I, intracellular vesicle and II, mitochondria. Cell surface 
features observed were: (B) cell membrane protrusions and (C) external cellular debris. NM, nuclear 
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As a result of baculovirus infection, numerous intracellular vesicles (20-400 nm across) were 
formed (Fig. 4.6B, C) and released from the cell upon lysis (Fig. 4.6D). This observation is 
significant to this study, since some of these vesicles may have a buoyant density equivalent to 
VLPs and would therefore be co-purified with VLPs by either see or SXc. This may in part 
account for the structures visible by apTEM from AcNPV -infected cells (Fig. 4.3F) . 
FIGURE 4.6. Effects of baculovirus infection on Sf21 cell morphology. 
Morphological features visible during baculovirus infection in Sf21 cells include: (A) Condensed 
baculovirus (CB) predominated in the nucleus, while the cytoplasm showed reduced numbers of 
organelles. Inset: baculovirus budding from the cell indicated by the arrowhead. (B) Extensive empty 
vesicular structures (EY) in the cytoplasm. (C) Numerous filled vesicular structures (FY) visible 
between the intact nuclear- and cell membranes. (D) Cell lysis, nuclear membrane (NM) formed lamella 
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To illustrate that these vesicles could not be mistaken for budding particles by tsTEM, two low 
magnification examples of r AcNPV -infected cells are provided (Fig. 4.7 A & B). The particles 
from THMgagRT (Fig. 4.7A), and to a lesser degree THMgagC (Fig. 4.7B), resemble some of 
the cytoplasmic vesicles in cross section, but were clearly extracellular with the cell membrane 
still intact. These micrographs also illustrate that the particles produced by THMgagRT (as well 
as FIMgagRT and Gag-RTTN fusion proteins, described in section 4.3.3.3) differed significantly 
from typical Gag VLPs (e.g. THMgagC, Fig. 4.7B) in several areas of ultrastructure. For this 
reason, these larger, less compact and heterogeneous particles are termed here as virus-derived 
particles (VDPs). 
4.3.3.1 Myr- Gali controls 
The expression of Myr - Gag proteins did not lead to the budding of VLPs from the cell, nor was 
there any noticeable increase in electron density at the cell membrane (data not shown), which is 
potentially indicative of protein localization. There was one distinct difference between 
H~MgagC and TH~MgagC expression: structurally ordered electron dense aggregatcs were 
visible in the nucleus for both constructs (Fig. 4.8A & 4.9A) but isolated structures in the 
cytoplasm were only visible for TH~MgagC (Fig. 4.9 A). The nuclear aggregates for both Myr 
Gag constructs were composed of individual 120 - 200 nm structures with 2 - 4 defined layers 
(Fig. 4.8B, C & 4.9D, E), which were always approximately circular in cross-section, and are 
therefore probably spherical rather than tubular structures. The cytoplasmic units from 
TH~MgagC resemble Gag VLPs (Fig. 1.2) but were often composed of 2 3 layers with less 
distinct electron dense rings (Fig. 4.9C). Immunogold labeling within the layers of all these 
structures confirmed they contain p24 (Fig. 4. lOA-G). AcNPV -infected cells showed no 
immunogold labeling (data not shown). 
4.3.3.2 Myr Gali controls 
The expression of both WTgagC and HMgagC was associated with the budding and release of 
VLPs (~100 nm in diameter) at the cell membrane (Fig. 4.11 A, B). Likewise, THMgagC 
produced abundant VLPs ~ 100 nm across (Fig. 4. 1 2A-E). VLPs showed an outer shell (-15 nm) 
surrounding an electron dense ring (Fig. 4.11A, inset ii). The center of the VLP was often 
translucent and immunogold labeling confirmed the presence of p24 (Fig. 4.13A), which was 
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FIGURE 4.7. Budded particles are distinguishable from cytoplasmic vesicular structures before 
cell lysis in Sf2l cells. Sf21 cells infected with rAc-THMgagRT (A) and rAc-THMgagC (B) are shown 
as examples. Budded particles at the cell surface were separated from cytoplasmic vesicles by the cell 
membrane. I, single baculovirus; II, condensed baculoviruses; III, vesicular structures in cytoplasm; 
IV, budding; V, VLPs and VDPs; VI, low melting point agarose used in embedding process; 
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FIGURE 4.8. Accumulation of HAMgagC structures in the nucleus. 
Sf21 cells infected with rAc-HL'1MgagC showed ordered structures present only in the nucleus, 
indicated by the arrows (A). Magnifications of these multilayered aggregations are shown in (8) and 
(C). 8ar = 500 nm (A), 100 nm (8, C) 
FIGURE 4.9. Accumulation of THAMgagC in the nucleus and cytoplasm. 
Sf21 cells infected with rAc-THL'1MgagC showed ordered structures present in both the nucleus and 
cytoplasm, indicated by I and II respectively (A) . Magnifications of cytoplasmic structures (8, C) and 
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FIGURE 4.10. Immunogold labelling of structures in cells expressing Hi\MgagC and THi\MgagC. 
Ultrathin unstained sections were probed with p24 antiserum and labelled with 10 nm colloidal gold 
conjugate . HL'lMgagC (A) and THL'lMgagC (8) structured aggregates rrom nucleus. THL'lMgagC 
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FIGURE 4.11. WTgagC and HMgagC VLPs. 
(A) WTgagC VLPs. Insets indicate (i) membrane curvature associated with budding (ii) the 
characteristic electron dense ring (white arrowhead) below the VLP periphery. (8) HMgagC VLPs. 
Bars = 100 nm (insets), 100 nm (A, B). 
FIGURE 4.12. THMgagC VLPs. 
Budding and release of extracellular VLPs from cells infected with rAc-THMgagC (A-E) . 
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FIGURE 4.13 . Immunogold labelling of HMgagC and THMgagC VLPs. 
Ultrathin unstained sections were probed with p24 antiserum and labelled with 10 nm colloidal gold 
conjugate. (A) THMgagC VLPs at the cell surface and specific labelling of the electron dense ring in a 
THMgagC VLP (B) and a HMgagC VLP (C). Bar = 100 nm (A), 100 nm (B, C). 
4.3.3.3 RTTN-derived Gag chimaeras 
81 
For each specific C-terminal fusion sequence (e.g. TN), the appearance of the budded particles 
was largely identical between HMgag- and THMgag-based chimaeras. However, the appearance 
of the particles varied significantly between chimaeras with different C-terminal fusion 
sequences. There seemed to be an overall trend that as the protein fusion length increased 
(from 113 - 778 aa), the particle size apparently increased but the average number of VLPs 
observed budding per cell decreased. 
HMgag3'RT and THMgag3'RT budded off compact, uniform VLPs with diameters of ~120 nm 
and ~ 100 nm respectively (Fig. 4.14A-J). Both were comparable in structure to Gag-only VLPs 
(compare to Fig 4. 11 and 4.12). HMgag3'TN and THMgag3'TN budded off slightly larger VLPs 
with considerable size heterogeneity compared to Gag-only VLPs, ranging in diameter from 
120 - 210 nm (Fig. 4.1SA-J). The HMgag3'TN VLPs in particular were often observed as 
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Interestingly, the constructs carrying the substantially longer TN fusion, generated similar sized 
VLPs to the Gag-3'TN constructs, ranging from 130-190 nm in diameter (Fig. 4.16A-J). In 
addition, the majority of these VLPs were observed intact, in contrast to the HMgag3 TN VLPs. 
HMgagRT and THMgagRT budded off even larger, less compact particles, ranging in diameter 
from 180 - 330 nm and 180 - 410 nm respectively (Fig. 4.17A-J). In this case, the THMgagRT 
VDPs were generally larger and more variable in size than those of HMgagRT. Both chimaeric 
VDPs often showed granular interiors with electron dense patches around the particle periphery 
as opposed to a defined electron dense ring. Some budded structures showed only a membrane in 
sections of the VDP periphery (e.g. Fig. 4.17 A, inset), and were up to 400 nm across for 
HMgagRT (Fig. 4.17B). This phenomenon of localized absence of Gag at the particle periphery 
has been observed in type I in-frame VLPs previously (Wagner et al., 1994a). The constructs 
carrying the longest fusion (778 aa), HMgagRTTN and THMgagRTTN, also budded off large 
VDPs with diameters of 170 - 320 nm for both (Fig. 4.18A-J). These Gag-RTTN VDPs exhibited 
a similar overall appearance to the Gag-RT VDPs. 
In a few ceUs, budding occurred into intracellular compartments (in addition to extracellular VLP 
formation), and a particularly striking example is provided in Figure 4.19. This phenomenon was 
observed in some cells expressing each construct, but was the exception rather than the rule. 
Ultrathin sections of cells expressing each RTTN-derived construct were reacted in separate 
experiments with 4 anti-Nef and 3 anti-RT antisera/antibodies under a range of conditions (E.2). 
In each case immnogold labeling was either absent or non-specific (binding to sectioned 
H:Y1gagC VLPs). The use of LR White™ Resin (London Resin Company), which is formulated 
for use in immunocytochemistry, did not improve immunogold labeling compared to Spurr's 
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HMgag3'RT 
THMgag3'RT 
FIGURE 4.14. HMgag3 'RT and THMgag3 'RT VLPs. 
Budding and release of extracellular VLPs from rAc-HMgag3'RT and rAc-THMgag3'RT infected 
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HMgag3'TN 
THMgag3'TN 
FIGURE 4.15. HMgag3 'TN and THMgag3 'TN VLPs. 
Budding and release of extracellular VLPs from rAc-HMgag3'TN and rAc-THMgag3'TN infected 
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HMgagTN 
THMgagTN 
FIGURE 4.16. HMgagTN and THMgagTN VLPs. 
Budding and release of extracellular VLPs from rAc-HMgagTN and rAc-THMgagTN infected cell s. 
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HMgagRT 
THMgagRT 
FIGURE 4. 17. HMgagRT and THMgagRT VDPs. 
Budding and release of extracellular VDPs from rAc-HMgagRT and rAc-THMgagRT infected cells. 
Inset (A): incompletely formed particle, arrowhead indicates where particle pinched off from the cell 
and only the cell derived membrane remains in this section of the structure. 











Chapter 4: Characterization of chimaeric Gag particles 
HMgagRTT!'i 
THMgagRTTN 
FIGURE 4. 18. HMgagRTTN and THMgagRTTN VDPs. 
Budding and release of extracellular VDPs from rAc-HMgagRTTN and rAc-THMgagRTTN infected 
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FIGURE 4.19. Example of VLP budding into intracellular compartments. 
This cell , infected with rAc-THMgag3 TN, showed high concentrations of VLPs that had budded into 
membrane bound regions within the cytoplasm. The compartment indicated with an asterisk is filled 
with both complete and partly formed particles. All Myr; Gag proteins exhibited this phenomenon to 
some extent. Budding at VLP formation was also present at the cell surface, and an extracellular VLP is 
shown with an arrowhead. Bar = 500 nm. 
88 
The size data for VLPs and VDPs from the RTTN-derived constructs is sununarized in Table 4.1 
and the correlation between fusion length and particle size is compared in Figure 4.22. 
4.3.3.4 Gag-PE chimaeras 
Surprisingly, HMgagPE and THMgagPE, which carry the second shortest of the fusions (155 aa), 
did not generate VLPs or even VDPs. Cells expressing Gag-PE constructs appeared to extrude 
irregularly sized blebs or vesicles, that rarely budded completely (Fig. 4.20A-J). In both cases, 
structures 250 - 400 nm across were most conunon (Fig. 4.20E, J), but structures measuring up to 
1 p,m were also observed. These structures could be distinguished from the polymorphic features 
at the cell membranes of Sf21 cells (Fig. 4.5) by their electron dense budding surface and 
predominantly spherical shape. In addition, cells expressing HMgagPE or THMgagPE showed 
unstructured electron dense cytoplasmic aggregations (Fig. 4.21). These were not seen in cells 
expressing other constructs or in uninfected controls. lnununogold labeling of sections probed 
with anti-SV5-Pk mAb could not confirm that extracellular blebs or cytoplasmic aggregates 




















TABLE 4.1. Diameters of chimaeric Gag VLPs and VDPs 
based on tsTEM measurements 
Range in Average 
Construct 1 diameter 2 diameter 3 SD 4 (n = 40) 
(nm) (nm) 
VLP controls 
WTgagC 95 - 120 106 6.8 
HMgagC 95 - 120 104 6.8 
THMgagC 95 - 110 103 4.1 
Gag chimaeras 
HMgag3'RT 105 - 135 122 7.7 
THMgag3'RT 95 - 110 106 4.8 
HMgag3TN 130 - 240 164 26.8 
THMgag3TN 115 - 200 149 28.8 
HMgagTN 125 - 195 158 19.3 
THMgagTN 120 - 160 138 11.2 
HMgagRT 155-290 224 41.9 
THMgagRT 170 - 410 270 67.6 
HMgagRTTN 155 - 290 233 46.7 
THMgagRTTN 170 - 300 243 39.0 
Gag-PE constructs omitted, as these constructs did not form discrete 
particles. 
2 Each value rounded to nearest 5 nm. Only intact VLPs were measured -
partly formed, disintegrated or fused particles were excluded. 
3 The diameter of each particle was measured twice on perpendicular axes 
since particles were often not completely circular in cross section. These 
mean values (n = 40) were then averaged. 
4 Standard deviation, rounded off to nearest decimal point. 
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FIGURE 4.22. Size of chimaeric particles in relation to fusion sequence length. 
Average particle diameter and standard deviation (error bars) based on tsTEM 
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HMgagPE 
THMgagPE 
FIGURE 4.20. Budded HMgagPE and THMgagPE blebs. 
Cell membrane associated blebs in cells infected with rAc-HMgagPE and rAc-THMgagPE. 
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FIGURE 4.21. Cytoplasmic HMgagPE and THMgagPE aggregations. 
Accumulation of cytoplasmic aggregations (not discernibly ordered) in rAc-HMgagPE and 
rAc-THMgagPE infected cells. Bars = 100 nm (A-D, F-I), 100 nm (E, J). 
4.3.4 sec of Sf9 suspension culture supernatant 
IEM was unsuccessful in confinning that the VLPs and VDPs seen by tsTEM contained the full-
length Gag chimaeras (by detecting the fusion component). Therefore, concentrated particle 
purifications were required so that the protein composition could be analyzed by western blot. 
Using sec and SXC, the levels of Gag-RT and Gag-RTIN were too low for this analysis, so 
SGC with 60 ml volumes of culture supernatant was conducted. This would also be the next step 
toward optimizing the production of VLPNDP batches for immunogenicity testing, so a 
suspension culture system using Sf9 cells was chosen. 
From the 10 RTTN-derived Gag chimaeras, the 5 fusions to HMgag (Fig. 2.10) were chosen for 
complete analysis of SGC samples. Evidence from western blots of culture supernatants (3.3.2.2), 
sec samples (4 .3.1.1), SXC samples (4.3.1.2) and tsTEM data (4.3.3.3) suggested that THMgag 
is not necessarily a superior carrier of larger antigens than HMgag. In this case HMgag-fusions 
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FIGURE 4.23. Purification of chimaeric HMgag-fusion VLPs and VDPs from Sf9 suspension culture using SGc. 
Particles were purified from Sf9 suspension cultures by centrifugation through a continuous sucrose gradient. Cells were infected with rAcNPV expressing 
the indicated constructs. In adjacent wells on the same gel (A-C), 30 J.l.I of SGC sample was loaded and membrane lanes were probed with p24-specific 
antiserum (p24), RT antiserum (RT) or anti-Nef mAb (Net) as indicated. Control proteins: +RT = 100 ng, +Nef = 50 ng. M = MW marker, 
10 Ab = primary antibody. 
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In western blots of purified preparations from the HMgag-fusion constructs (Fig. 4.23), samples 
were run in adjacent lanes on a single blot to confirm that different primary antisera/antibodies 
were indeed detecting the same band. The full-length proteins were present in all SOC samples, 
providing strong evidence that at least some of the particles visible by tsTEM for the 
corresponding constructs were composed of the complete chimaera. apTEM of the HMgag-fusion 
SOC samples (Fig. 4.23) confilmed the presence of particles of comparable size to those visible 
by tsTEM (Fig. 4.24). However, these particles were not highly concentrated in the samples used 
to prepare EM grids, particularly for the HMgagRT and HMgagRTTN SOC samples. 
The 5 THMgag-fusions with RTTN components (Fig. 2.10) were also detected in initial SOC 
sample preparations (by western blot with p24-specific antiserum), but at a lower intensity than 
HMgag-fusions under the same conditions (data not shown). In pooled SOC preparations 
(from 120 ml of culture supernatant), each Oag-PE protein was just detectable with anti-SV5-Pk 
mAb, but not with p24-specific antiserum (data not shown). 
FIGURE 4.24. Structures resembling VLPs are present in Sf9 SGC samples. 
The HMgag-fusion SGC samples were analyzed by apTEM : (A) HMgagC (8) HMgag3 'RT (C) 
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4.4 DISCUSSION 
The expression of WTgagC, HMgagC and THMgagC led to the production of VLPs, which were 
indistinguishable from one another. The absence ofp6 did not preclude VLP formation or visibly 
affect the particle morphology, consistent with previous reports using the baculovirus system 
(Royer et aI., 1991; Jowett et at., 1992; Griffiths et al., 1993). This observation supports the 
theory that p6 does not contribute to critical Gag-Gag interactions during immature HIV -I virion 
assembly and release (Wang et al., 1998; Spearman et al., 1994). Furthermore, p6 does not 
appear to affect VLP size, unlike HIV virions where p6 has been shown to be a principle 
determinant of virion size, and the removal of p6 led to the production of very large HIV particles 
(Gamier et at., 1998). It has been suggested that p6 is required for efficient detachment of 
budding virions from the cell membrane (Yu et al., 1995), but the results of this study indicate 
that this L-domain function of p6 does not extend to Gag or chimaeric Gag VLPs produced in 
insect cells. Expression of the Myr- Gag controls caused defined Gag microstructures to form 
within the cell but did not lead to membrane association of Gag, or the budding and release of 
extracellular VLPs. These results confirm that myristylation is required for VLP formation 
(Gheysen et al., 1989), and support suggestions that it is involved primarily in forming stable 
membrane associations (Bryant & Ratner, 1990; Resh, 2004) rather than Gag multimerization 
(Morikawa et al., 2000), which can occur in the absence of membranes (Gross et at., 1998). It 
was noted that the expression of Myr+ Gag controls caused decreased adhesion of cells in 
monolayer culture relative to those expressing Myr Gag. Most likely, the budding and release of 
VLPs from the cell surface promoted cellular detachment. 
The accumulation of H~MgagC (which is synthesized in the cytoplasm) in the nucleus suggests 
that Pr5Sgag contains one or more nuclear localization signals (NLSs) that are suppressed in the 
Myr+ protein. Since THMgagC accumulates in the cytoplasm in addition to the nucleus, p6 may 
contain its own NLS that could function synergistically with others in Gag (there are two present 
in MA (Scarlata & Carter, 2003» to cause the complete nuclear import evident in H~MgagC 
expressing cells. Alternatively, the presence of p6 may increase the functionality of other NLSs 
in distant domains. Royer et al. reported similar results for analogous constructs in insect cells, 
but they noticed no morphological difference between nuclear and cytoplasmic structures (Royer 
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Furthermore, low levels of Myr- Pr55gag clusters were found in the cytoplasm (Royer et aI., 
1991), whereas in this study these were not observed in rAc-H~MgagC infected cells. The latter 
may be due to a difference in NLS sequences, as the two potential karyophilic signals that were 
identified in their Gag construct sequences (KKKYKLKH and KSKKKA, (Royer et aI., 1991» 
are not present in H~MgagC (F.l). 
The nuclear aggregations from Myr Gag constructs (Fig. 4.8B & 4.9D) showed indistinguishable 
structure using tsTEM, and therefore it is unlikely that p6 plays an important role in the assembly 
of these multilayered structures. Since TH~MgagC showed individual structures in the cytoplasm 
resembling VLPs, but larger aggregations in the nucleus, there may be a concentration-dependent 
effect controlling the type of structure formed. Alternatively, micro-environmental properties of 
the cytoplasm and nucleus may govern what structure will form in each region. 
The budding of RTTN-derived particles at the cell surface agrees with IIF evidence for the 
localization of the RTTN-derived chimaeric proteins to the cell membrane (3.3.3.2). HMgag- and 
THMgag-based chimaeras carrying the same C-terminal sequence produced comparable particles 
(based on size and ultrastructure visible by tsTEM) for all RTTN-derived fusions. Therefore, for 
this set of chimaeras, the removal of p6 in the Gag carrier did not obviously alter particle 
morphology, and HMgagC could incorporate the same length C-terminal fusions as THMgagC. 
Griffiths et al. observed that ~50% ofVLPs produced from in-frame V3 fusions to a p6-truncated 
Gag were found in the nucleus of insect cells (Griffiths et aI., 1993), but this was not observed for 
any of the Myr + chimaeric Gag constructs in this study. It would appear that in the absence of p6, 
the V3 sequence interfered with cellular localization of the chimaeric protein, whereas in this 
study the fusion sequences did not have this effect. 
Expression of Gag fused with 3 'RT, 3 'TN and TN led to the production of budded particles that 
exhibited a typical Pr55gag VLP structure in cross section. TN was -120 aa longer than the 
hypothesized limit (Deml et al., 2005) for an in-frame fusion to Gag that would allow VLP 
formation. HMgagTN and THMgagTN carry the longest fusion within a type I in-frame VLP 
reported to date. The particles formed by expressing Gag-RT and Gag-RTTN constructs appear 
less compact, more granular and do not generally have a distinct electron dense ring of protein 
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proteins (Fig. 4.16 & 4.17) shows a clear transition from typical VLP morphology 
(Gag-TN VLPs) to budded particles with a less defined internal structure (Gag-RT VDPs). The 
Gag-RT and Gag-RTTN particles, termed here as VDPs, have in-frame fusions of 450 and 778 aa 
respectively. The Gag-RTTN VDPs carry the longest in-frame fusion to gag reported to date, that 
has still produced extracellular particles in the baculovirus system, albeit with diferring 
ultrastructure to typical VLPs. 
As the length of RTTN-derived fusions increased, the resultant chimaeric particles appeared 
larger (rising from ~ 100 nm to -250 nm in average diameter), less compact in structure and more 
variable in size. However, there were exceptions to this trend. Thus, although the full TN 
polypeptide (322 aa) is almost double the length of the 3 'TN polypeptide (169 aa), HMgag- and 
THMgag- fusions with TN generated similar sized VLPs to corresponding fusions with 3 'TN. 
Likewise, the -RTTN (778 aa) fusions did not generate larger VDPs than -RT (450 aa) fusions; 
in fact the largest VDPs (up to 410 nm in diameter) were from THMgagRT. The VLP and VDP 
sizes based on average tsTEM measurements (Table 4.1) are most likely less than the actual 
average particle dimensions, since sections that do not pass through the center of the particle will 
show structures of smaller diameter. Therefore, the actual size range and heterogeneity of 
particles for each construct may be lower than is apparent from these measurements. 
The chimaeric RTTN-derived particles can be purified from Sf9 suspension culture supernatant 
by SGc. The bands of lower MW observed in western blots for HMgagRT and HMgagRTTN 
(Fig. 4.23C), suggest that some of the particles visible by tsTEM may be composed of individual 
breakdown products or a combination of such proteins. This may paltly account for the apparent 
size heterogeneity in the larger VDPs. However, the presence of the full-length protein band in 
SGC samples is sufficient evidence to show that chima eric Gag particles with large in-frame 
C-terminal fusions (up to 778 aa) can be produced, which was not though possible until this 
study. This greatly expands the use of Gag-based antigen carriers as candidate HIV-l vaccines. 
Pr55gag chimaeras with long C-terminal polypeptide additions have been reported previously 
(zur Megede et ai., 2003; Young et al., 2004; Buonaguro et al., 2001). Zur Megede et al. 
constructed vaccine plasmids encoding several variants on Gag-Pol in-frame C-terminal fusions 
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made a construct that encoded a C-tenninal fusion to PrSSgag of inactivated HIV-l PR and RT, 
which was larger (149 kDa) than the largest construct in this study (HMgagRTTN, 144 kDa), 
Gag proteins from this construct were not detectable in the culture supernatant of transfected 
HEK293 cells by western blot. Young et af. made DNA vaccines expressing larger Gag-Pol 
chimaeras that were capable of fonning VLPs in primate cell lines (Young et af., 2004). 
However, these were generated by making use of the gag-pol frameshift signal, so that the added 
DNA sequence was in the same frame as pol. Consequently, only 5% or less of the Gag 
molecules in the resultant VLP would be expected to carry the extended protein sequence 
(Jacks et al., 1988; Wilson et al., 1988). Likewise, Buonaguro et al. used gag-pol ribosomal 
frameshifting to express Gag-Pol-Nef(~160 kDa) chimaeric VLPs (Buonaguro et al., 2001), and 
Tobin et af. expressed chimaeric VLPs incorporating the C -terminal 273 aa of HIV -1 gp 120 
(Tobin et al., 1997) - both groups used a baculovirus system. 
In the present study, gag sequences were used where the gag-pol frameshift signal had been 
eliminated through prior sequence alteration to reflect optimal human codon usage (van 
Hannelen et aZ., 2003). Thus, the 3 '-tenninal gene fusions in this study were in the same frame as 
the gag gene sequence, allowing for the expression of chimaeric VLPs incorporating a 1: 1 ratio 
of Gag carrier protein to polypeptide insert. Thus, each VLP would in theory carry approximately 
20-fold more fused polypeptide antigen than would result from the gag-pol frameshifting 
approaeh, so that these type I in-frame VLPs would be anticipated to show greater fusion 
sequence-specific immunogenicity than would type I frameshift VLPs carrying the same fusion. 
The phenomenon of Pr5Sgag VLP (Royer et al., 1991; Vernon et al., 1991, A. Jaffray, pers. 
comm.) and type I in-frame VLP (Brand et al., 1995) budding into cytoplasmic vesicles has been 
reported previously, and was demonstrated for all chimaeric RTTN-derived constructs in some of 
the rAcNPV-infected cells. This agrees with IIF results (3.3.3.2), where defined regions of 
cytoplasmic IIF staining were observed in some cells in addition to cell membrane staining. Even 
if this occurs at a low overall level, the particle yield in purification strategies could potentially be 
increased by the incorporation of cell lysate, although this may complicate the protocol. 
Although the relative particle yields from the RTTN-derived fusions could not be quantified 
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(Fig. 3.3) and numbers of particles budding per cell (tsTEM observations, Fig. 4.14 - 4.18) 
suggests a trend that particle yield decreases with chimaeric protein size. A similar trend has been 
noted previously for Env-derived C-terminal Gag fusions (Luo et al., 1992). 
Expression of the Gag-PE constructs in insect cells did not lead to VLP or VDP production. 
Rather the cells extruded irregular blebs and accumulated unstructured electron dense 
aggregations in the cytoplasm. Since the Gag-PE constructs produced similar intracellular- but 
lower extracellular levels of protein (3.3.2.3), and far fewer budding structures than the 
RTTN-derived constructs, these aggregations are hypothesized to be composed of chimaeric 
protein that remains in the cell. This hypothesis could not be proven with IEM, but was supported 
by IIF results (3.3.3.3). The low levels of Gag-PE proteins that could be detected in SGC samples 
(4.3.4) may have been due to the release of these aggregates into the culture medium (from 
limited cell lysis) in conjunction with the co-purification of the extracellular blebs (Fig. 4.20). 
The fact that neither Gag-PE construct formed particles, whereas all RTTN-derived constructs 
formed either VLPs or VDPs, suggests that sequence composition, in addition to sequence length, 
plays a critical role in chimaeric Gag particle formation. PE is 155 aa long, and although shorter 
C-terminal Gag-fusions have not produced VLPs (Table 1.2), -3TN (169 aa) and -TN (322 aa) 
fusions in this study did produce VLPs, and the fusion of RTTN (~5x longer than PE) to Gag 
carriers produced VDPs. Therefore, sequence composition may have more influence than 
sequence length per se on tolerable C-terminal fusions that can produce chimaeric Gag particles. 
Particle formation is probably dependent on permissible protein interactions between the Gag 
carrier molecule and the fusion protein or peptide, along with the folding of the fusion component 
into an overall structure that does not sterically hinder particle assembly. It is possible that the 
artificial PE fusion adopted conformations that inhibited particle assembly in this manner without 
preventing membrane binding. Furthermore, it is possible that the presence or absence of the p6 
region may indeed affect VLP formation for other C-terminal fusion sequences, even though this 
was not the case any of the fusion sequences used in this study. Ultimately, the length and 
sequence limitations of fusions relative to a specific Gag carrier that can be packaged into VLPs 
(as either C-terminal or internal Gag fusions) need to be empirically determined, as there is no 
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CHAPTERS 
Conclusions 
The development of an effective HIV vaccine is one of the greatest challenges facing mankind in 
the 21 st century. In 2005, an estimated 7 400 people were newly infected with HIV each day in 
sub-Saharan Africa alone (UNAIDS, 2006). In a geographical region with over 12 million AIDS 
orphans in 2005 (UNAIDS, 2006), where the vast majority of AIDS patients do not have access 
to antiretroviral therapy, the need for a preventative HIV vaccine cannot be over-emphasized. 
Since traditional vaccine approaches have failed to elicit NAb responses to HIV (Letvin, 2005), 
novel vaccine approaches have been increasingly pursued. Chima eric Gag VLPs are one such 
novel vaccine strategy that has shown encouraging results for stimulating cellular immune 
responses (Deml et al., 2005; Wagner et aI., 1996b). Furthermore, since HIV-IC Pr55 gag VLPs 
successfully boosted murine immune responses to a pTHgagC DNA vaccine prime (Jaffray et al., 
2004), chimaeric Gag VLPs may boost the immune responses to DNA vaccines such as 
pTHr.HIVA and pTHr.grttnc. 
In this study, 12 chimaeric Gag proteins were constructed and tested for their ability to form 
VLPs in insect cells using the baculovirus system. During this process a number of reported 
functions of the myristylation signal and p6 within PrSSgag were reaffirmed. Myristylation was 
required for extracellular VLP formation but not Gag multimerization, and may contribute to Gag 
membrane targeting by suppressing NLSs in Gag. The absence of p6 did not affect the formation, 
release, size or ultrastructure of Gag-only VLPs, and p6 may contain a NLS or enhance the 
function ofNLSs elsewhere in Gag. 
This study demonstrated that PrSSgag and PrSOgag could tolerate far longer C-terminal polypeptide 
fusions additions than previously estimated, while still forming regular budded particles. It was 
also demonstrated, for RTTN-derived fusions at least, that the presence or absence of the p6 
region of Gag does not have an impact on the length of polypeptide that can be carried 
C-terminally by Gag, or on the overall appearance and size of the particle formed by a specific 
chimaeric Gag protein. However, particle yield in Sf9 cells was apparently higher for constructs 
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A 322 aa fusion (TN) to Gag fonned typical VLPs, while the full RTTN polyantigen (778 aa), 
which is almost twice the length of Pr50gag itself, can be incorporated into an exact VDP 
analogue (THMgagRTTN) of the pTHr.grttnC DNA vaccine. In practice however, shorter 
chimaeras that produce higher yields of uniform VLPs, as opposed to lower yields of VDPs from 
longer chimaeras may be preferable for vaccine preparation purposes. Therefore, long protein 
additions (e.g. RT) could be carried in sections by several shorter chimaeras (e.g. HMgag3'RT) 
in a heterogeneous VLP preparation. However, the larger VDP chimeras (e.g. HMgagRT) are 
potentially more immunogenic and may elicit strong immune responses at lower doses. 
Unlike any of the RTTN-derived Gag fusion proteins, the Gag-PE chimaeras did not fonn VLPs 
or VDPs. Therefore, a particle-based analogue to pTHr.HIV A could not be reliably produced. 
This was a surprising result given that PE (155 aa) was within the hypothesized fusion length 
limit of ~200 aa. Moreover, Gag-PE chimaeras have a fusion sequence that is ~5x shorter than 
the Gag-RTTN chimaeras, which fonned VDPs. Therefore, it appears that the sequence 
composition of the fusion may have a greater bearing than sequence length per se on chimaeric 
Gag particle fonnation, at least for C-tenninal Gag fusions. 
The fusion length limit of ~200 aa for type I in-frame VLPs proposed by Deml et al. (Deml et aI., 
2005) was based almost exclusively on VLPs with V3- and CD4BD-derived fusions (Table 1.1). 
The apparent importance of fusion sequence composition in type I in-frame VLP fonnation may 
reconcile the difference in tolerable fusion length observed in this study compared to the 
previously proposed limit. Although artificial polypeptides allow for the concentration of 
immunological epitopes in a small sequence space, our contrasting results obtained with Gag-PE 
and Gag-TN (shuffled epitope fusion sequence) suggest that artificial polypeptides must be tested 
empirically for VLP fonnation. The results with Gag-RT and Gag-RTTN chimaeras suggest that 
predominantly native peptide sequences may be preferable for generating chima eric Gag VLPs 
with long fusions, and should be considered in future chimaeric Gag VLP design. 
Recent work by Masemola et al. indicated that the majority of T-cell responses against HIV -1 C 
proteins in humans were directed against Nef, Gag and Pol components, in this hierarchical order 
(Masemola et al., 2004). Based on these data, the chimaeric Gag particles produced in this study 










Chapter 5: Conclusions 101 
immunogenicity testing of selected constructs, probably starting in a mouse model. To this end, 
the titre of rAcNPV stocks would need to be determined, so that the optimal MOL for particle 
production from selected constructs in Sf'} cells could be obtained. The visualization of the 
particle band in the sucrose density gradient by white light trans-illumination is a convenient 
method for particle purification, but the same density range is not reliably selected in replicate 
purifications. Complete sucrose sedimentation analysis of selected constructs should allow for the 
concentration, purity and reproducibility of particle preparations to be improved by defining a 
constant fraction for purifying particles. Although apTEM was not suitable in this study for 
determining which chimaeras formed particles, this technique has application in assessing the 
quality of concentrated particle preparations to be used in immunogenicity testing. 
Although it was possible to make a direct VDP analogue to pTHr.grttnC (THMgagRTTN), 
apparently only relatively low culture supernatant protein levels and VDP yields from either 
THMgagRTTN or HMgagKITN were observed. HMgagTN is probably the most promising 
individual candidate HIV -1 vaccine produced in this study based on particle composition, 
structure and apparent yield. Therefore, a combination of HMgagTN and HMgagRT particles 
offers an attractive boost antigen combination to pTHr.grttnC. Evaluation of the CTL responses 
to HMgagTN and HMgagRT in mice should confirm whether this proposed prime-boost strategy 
with pTHr.grttnC is worth pursuing further. 
In conclusion, this study has provided evidence that depending on the sequence composition, 
type I in-frame VLPs can tolerate much longer foreign gene sequences than previously thought 
possible. This greatly expands on the application of chimaeric Gag particles as candidate HIV-l 
vaccine candidates. Herein, 10 HIV -1 C VLP and VDP vaccine candidates have been produced, 
and should immunogenicity testing of selected particles in mice show favourable immune 
responses, these selected particles will be used in a prime-boost vaccination trial with 
pTHr.grttnC in primates. Such a vaccination regime, with HIV -1 C based antigens, is applicable 
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Appendix A - Reagents and standard methods 
A.I Bacterial strains and growth conditions 
coli DH5a™ and DHIOBac™ (Invitrogen) were cultivated at 37°C in Luria-Bcrtani (LB) 
broth with agitation, while LB agar plates contained 1.5% Bacto Agar. Ampicillin (100 p,g/ml), 
kanamycin (50 p,glml), gentamycin (7 p,glml), tetracycline (10 p,glml) isopropyl-fj-D-
thiogalactopyranoside (IPTG, 40 p,g/ml) and 5-bromo-4-chloro-3-indolyl-fj-D-galactopyranoside 
(X-gal, 100 p,glml) were added to the medium where necessary. 
A.2 Reagents and buffers 
Reagents 
All restriction and DNA modification enzymes were purchased from Roche, antibiotics were 
obtained from Sigma and all other chemicals were reagent grade or better. 
Buffers 
PBS (8 mM Na2HP04, 1.5 mM KH2P04, 140 mM NaCI, 2.5 mM KCl; pH 7.4) 
SDS-PAGE 
5x sample loading buffer (315 mM Tris-HCl, 10% (w/v) SDS, 40% glycerol, 40% 2-mercapto-
ethanol, 0.025% bromophenol blue; pH6.8) 
Western blotting 
Transfer buffer (50 mM Tris base, 40 mM glycine, 20% (v/v) methanol; pH 9.2) 
Blocking buffer (3% (w/v) BSA, 0.1 % (v/v) Tween 20 in PBS) 
Washing buffer (0.1 % (v/v) Tween 20 in PBS) 
IIF 
PBS-IIF (10 mM Na2HP04, 2.5 mM NaH2P04, 140 mM NaCl; pH 7.4) 











A.3 DNA preparation and manipulation 
All bacterial plasmids were maintained in E. coli DHSa™ (Invitrogen). Plasmid preparations 
were obtained by using the Plasmid Mini Prep Kit (QIAGEN®) following manufacturer's 
instructions, and DNA concentration was determined by measuring absorbance at 260 nm with a 
'\JanoDrop ND-lOOO Spectrophotometer. Restriction endonucleases, T 4 ligase, shrimp alkaline 
phosphatase, mung bean nuclease, Klenow enzyme and appropriate enzyme buffers were used in 
cloning strategies as specified by the manufacturer (Roche). Restriction enzyme digest fragments 
and PCR products were purified from 0.8% agarose gels (Sambrook et al., 2001) using the High 
Pure PCR Product purification kit (Roche). 
A.4 DNA sequencing 
Sequencing reactions were performed with the DYEnamic™ ET Dye Terminator Cycle 
Sequencing Kit for MegaBACE™ (Amersham Pharmacia Biotech) according to manufacturer's 
instructions. Cycle sequencing products were synthesized using primers FBDS 1, HMgagS 1 
(Table 2.2) or pUC/M13 forward and reverse sequencing primers (Promega, Cat.# QS601lQ5421 
respectively), Thermo Sequenase™ II DNA polymerase and the thermocycler cited above. These 
products were analyzed on a MegaBACE 500™ sequencer (Amersham Pharmacia Biotech) and 











A.5 Bac-to-Bac® Baculovirus Expression System 
pFast8ac ,. donor plasmid 
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FIGURE A.I. Generation of recombinant baculovirus using the Bac-to-Bac:!(' Baculovirus 
Expresion System. The gene of interest is cloned into a pFastBacT:"vl donor plasmid (such as 
pFastBac™Dual) as a mini-Tn7 element under either the ~ I 0 or Polh promoter. The recombinant donor 
plasmid is transfom1ed into competent E. coli DHIOBac M cells containing a resident bacmid (with a 
mini-auTn7 target site) and a helper plasmid. The bacmid lacZa gene compliments a lacZ delection on 
the bacterial chromosome to produce blue colonies in the presence of a chromogenic substrate 
(e.g. X-gal) and the inducer IPTG. Transposition proteins provided in trans by the helper plasmid allow 
for the mini-Tn7 element in the donor vector to be transposed into the bacmid mini-attTn7 target site. 
Successful transposition disrupts the lacZa gene and white colonies containing recombinant bacmids 
can be selected. Bacmid DNA is transfected into insect cells to generate recombinant baculovirus 
expressing the gene of interest, and plaque assays are the recommended method to determine the viral 












Appendix B - Polymerase chain reaction (peR) parameters 
The PCR parameters are listed in PCR-i, with only the changes from this protocol given for 
subsequent PCR reactions. Plasmids and primers are detailed in section 2.2.1. 
B.l PCR-l 
Amplification of the 5' region of gag (with abrogated myristylation signal) in pTHgagC was 
done using a Mastercycler:ID Gradient PCR machine (EppendorfID) with the primers HMgagFl and 
HMgagRl. Site directed mutagenesis (Cs""'" G5) within gag restores the myristylation signaL 
Approximately 5 ng of pTHgagC was used as template in a final reaction volume of 50 III 
containing: 100 liM dNTPs, 1.5 mM MgCh , 2.5U Super-Therm@ DNA polymerase (Southern 
Cross Biotechnology), 1 xSuper-Therm@ reaction buffer and 10 pM of each required primer. An 
initial denaturation step at 94°C (2 min) was followed by 30 cycles of denaturation at 94°C (30 
s), annealing at 63°C (30 s), and elongation at noe (30 s). A final extension was performed at 
72°C (1 min). 
B.2 PCR-2 
A BamHI site was introduced at the 5' end of gag using primers HMgagF2 and HMgagRl, with 
approximately 1 ng of PCR-l product as template DNA. The annealing temperatures during the 
30 cycles of amplification were as follows: 3 cycles at 63°C, 3 cycles 54°e and 24 cycles 63°C. 
B.3 PCR-3 
To remove the Gag stop codon (TAA), the 3' end of gag in pTHgagC was amplified with primers 
HMgagF3 and HMgagR2. In this case the annealing temperature was 56°C and elongation 
occurred for 1 min. 
B.4 PCR-4 
A stop codon (T AA) was inserted immediately downstream of the Bg/I site in gag (upstream of 
p6). Primers HMgagF3 and HMgagR3 were used to amplifying the NarI-BgII region of gag in 











Appendix C - pFastBac™Dual vector map 
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FIGURE C.l. pFastBac™Dual: vector map and pPolh Mes. 
Protein encoding sequences to be expressed by recombinant baculovirus in insect cell culture are 
cloned into the MCS downstream of the Polh promoter. 
S01lrce: Bac-to-Bac® Baculovirus Expression Systems, Instruction Manual, CAT. NO. 10359-












Appendix D - Restriction enzyme digests of new plasmids. 
TABLE D.l. Conformation of new plasmids by restriction enzyme digest patterns 
Plasmid I Size Restriction Digestion products 3 
(bp) enzyme(s) 2 (bp) 
Sub-cloning plasmids 
pGEM-5'HMgag 3611 EcoRI 614,2997 
A Iw44 I 927, 1246, 1438 
pGEM-3 'HgagNS 3984 EcoRI 18,969,2997 
pGEM-3 THgag 3837 £CaRl 18,822,2997 
pFBD-5'HMgag 5817 BamHl, EcoRI 601,5216 
lIindIll 666,5151 
BglI 1268,2041,2508 
pFBD-THMgagNS 6560 Alw44I 225, 1223, 1246, 1768,2098 
BamHI, EcoRJ 1344,5216 
Bgil 705,1268,2079,2508 
BglIJ 470,6090 
Hind III 1409,5151 




Gag control proteins 
pFBD-WTgagC 6765 EcoRI, Sail 1543,5222 
Alw441 1246,1768,3751 
Pstl 963,5802 
pFBD-HMgagC 6713 EcoRI, NarI 956,5757 
BamHl, Eco RI 1497,5216 
BglI 858,1268,2079,2508 
pFBD-THMgagC 6563 EcoRI, Nar1 806, 5757 
HindIII 1412,5151 
Sac! 357,6206 
pFBD-Hi1MgagC 4 6707 HindJI 181, 2471 , 4061 
Nco! 317,6397 
pFBD-THi1MgagC 4 6557 HindJI 181,2321,4061 
Plasm ids expressing 
chima eric Gag proteins 
pFBD-HMgag3' RT 6997 Alw44I, EcoRI 225,834,1223,1246,1701,1768 
BamHI 1789,5208 
EcoRI, NotI 323,6674 
Pvull 1972,5025 
pFBD-THMgag3'RT 6847 Alw44I, EcoRI 225,684,1223,1246,1701,1768 
BamHl 1639,5208 
EcoRl, Notl 323,6524 
Pvull 1822,5025 
pFBD-HMgagPE 7147 Alw44I, EcoRI 225,294,834,1223,1246,1557,1768 
PvuII 1968,5178 
XhoI 2264,4883 













Plasmid I Size Restriction Digestion products -
(bp) enzymc(s) 2 (bp) 
pFBD-HMgag3 'TN 7176 Alw44L EcoRI 225,510,834,1223,1246,1370,1768 
EcoRI 510,6666 
NarI, Xbal 506,963,5707 
Pstl 464,6712 
pFBD-TH:vlgag3 TN 7026 Alw441, EcoRI 225,510,684,1223,1246,1370,1768 
EcoRI 510,6516 
NarI, Xbal 506,813,5707 








pFBD-HMgagRT 8035 Alw441, EcoRI 225,834, 1044, 1223, 1246, 1695, 1768 
Bgll 1268,2079,2180,2508 
EcoRI, Notl 1361, 6674 
pFBD-THMgagRT 7885 Alw44I, EcoRI 225,684, 1044, 1223, 1246, 1695, 1768 
Bgli 1268,2030,2079,2508 
EcoRI, NotI 1361,6524 
pFBD-HMgagRTTN 4 9047 BglI 219,807,1268,2079,2166,2508 
EcoRI 2337,6710 
HindIIl 1040,2856,5151 
pFBD-THMgagRTTN 4 8897 EcoRI, 2337,6560 
HindIII 1040,2706,5151 
Narl 2640,6257 
I Plasmid backbone abbreviations: pGEM = pGEM® - T Easy, pFBD pFastBac™Dual. Encoded Gag proteins 
in pFBD plasmids are detailed in Fig. 2.10. 
Restriction enzymes were chosen based on important cloning sites within the plasmid backbone and insert. 
Digestion with Alw441 and EcoRI differentiates between HMgag- and THMgag-based constructs (834bp and 
684bp fragments respectively). 
) Expected digestion products were calculated using DNAMAN© version 4.13 (L)l1nOn Biosoft) and the banding 
patterns were confirmed by agarose gel electrophoresis of digested plasmids. 
4 Where cloning was non-directional, the expected fragments for an insert in the incorrect orientation are as 
follows: pFBD-HMgagRTfN (HindIIl: 1439,2457,5151), pFBD-THMgagRTTN (HindlIl: 1439,2307,5151), 
pFBD-HilMgagC (HindlI: 1015,1509,4061; Neal: 1859,4854) and pFBD-THM1gagC (HindII: 1015, 1487, 












Appendix E - Antisera and antibodies tested for use in IIF and IEM. 
E.1 IIF 
The antisera and antibodies ARP319, ARP432 (Table 3.2, 3.2.5); ARP313, ARP431 and 07320 
(Table E.l) were used in IIF staining of rAcNPV infected Sf21 cells expressing HMgagC, 
THMgagC, H~MgagC and TH~MgagC as well as an AcNPV negative control. No IIF staining 
could be detected using ARP319 and ARP313 with FITC conjugated anti-mouse IgG (1 :500, 
Sigma). Probing with D7320 and secondary anti-sheep FITC conjugate (1 :500, Sigma) also 
showed no IIF staining. When cells were probed with ARP431 and ARP432, the Gag expressing 
cells showed IIF staining that could not be readily differentiated from that of AcNPV infected 
cells (detection Alexa Flour® goat anti-rabbit, Molecular Probes) 
TABLE E.l. Additional primary antisera and antibodies used in IIF 
Antigen Host Dilution Details Designation Source 
p24 Mouse 1:500 Monoclonal antibody to HIV -I p24/p55. ARP313 
R. Fern and 
R. Tedder 1 
! Polyclonal antiserum to recombinant G. Reid 1 : pl7 Rabbit 1:500 
HIV-I HXB2 pl7 GST (E.coli). 
ARP43 I 
p24 sheep 1:500 
Affinity purified polyclonal antiserum to 
07320 
Aalto Bio 
HIV-I p24. Reagents 2 
RT Mouse 1:500 
Monoclonal antibody to HIV-I RT. Mapped 
ARP384 
R. Fern and 
to C-terminus (aa 431-531 ) R. Tedder 1 
1 National Institute for Biological Standards and Control (NIBSC), Centralised Facility for AIDS Reagents, 
Medical Research Council (MRC), United Kingdom (UK). 












The antisera and antibodies ARP444, EV A3067 .4, EVA 3068.2 (Table E.2); ARP428, 01-003, 
EVA3066 (Table 3.2, 3.2.5); EVA3018 (Table 3.4, 3.3.6) and ARP384 (Table E.1) were used in 
an IEM protocol (4.2.4.3) in an attempt to detect the RTTN-derived fusion components within 
chimaeric Gag particles. Results are summarized in Table E.3. 
TABLE E.2. Additional primary antisera and antibodies tested in IEM 
Antigen Host Specificity Designation Source 
- -_ ........ -
Nef Sheep Polyclonal antiserum to HIV-I GST Nef ARP444 M. Harris I 
Nef Mouse 
Monoclonal antibody to HIV-J BRU Nef. 
EVA3067.4 K. Krohn I 
mapped to aa 161-180 
Nef Mouse 
Monoclonal antibody to HIV-I JR-CSF Nef, 
EVA3068.2 K. Krohn I 
mapped to aa 193-206 
I National Institute for Biological Standards and Control (NIBSC), Centralised Facility for 
AIDS Reagents, Medical Research Council (MRC), United Kingdom (UK). 
TABLE E.3. IEM with antisera/antibodies to the fusion components of Gag chimaeras 
Antigen Antibody I Dilutions Resin Samples 2 Result 3 
SV5-Pk EVA3066 
1:50,1:100, Spurr's and 
HMgagPE and THMgagPE NS 
I :200, 1:400 LR White™ 
RT ARP428 
1 :50, 1:100, Spurr's and 
HMgagRT and HMgag3'RT NS 
I :200, 1:400 LR White™ 
RT ARP384 1:50,1:100 Spurr's HMgagRT and HMgag3'RT ILA 
RT EVA3018 1:50,1:100 Spurr's HMgagRT and HMgag3'RT ILA 
Ner 01-003 
1 :50, I: 100, Spurr's and 
HMgagTN and HMgag3'TN NS 
1:200, 1 :400 LR White™ 
Nef ARP444 1:50,1:100 Spurr's HMgagTN and HMgag3 TN NS 
Nef EVA3068.2 1 :50, 1:100 Spurr's HMgagTN and HMgag3 'TN ILA 
Nef EVA3067.4 1:50,1:100 Spurr's HMgagTN and HMgag3TN ILA 
Detected with anti-sheep and anti-mouse 10 nm colloidal gold conjugate as appropriate (I :50, Sigma). 
[n each case HMgagC was included as a negative control. 
Same overall result was observed in each instance. 
NS = Non-specific immunogold labeling, could not be differentiated from the negative control. 











Appendix F - Amino acid sequences 
F.l Amino acid sequences of Gag control proteins 
Note,' All constructs correspond to protein sequence !Tom the start codon of Gag (A TG) until the stop 
codon (TAG, T AA or TGA) of the protein-encoding sequence, 
HMgagC (492 aa) 
1 MGARASILRG EKLDKWEKIR LRPGGKKHYM LKHIVWASRE 
61 MKQLQPALQT GTEELKSLYN TVATLYCVHE KIEVRDTKEA 
121 ADGKVSQNYP IVQNLQGQMV HQAISPRTLN AWVKVIEEKA 
181 LNTMLNTVGG HQAAMQMLKD TINEEAAEWD RLHPVHAGPI 
241 QEQIAWMTSN PPIPVGDIYK RWIILGLNKI VRMYSPVSIL 
301 LRAEQATQEV KNWMTDTLLV QNANPDCKTI LRALGPGATL 
361 AEAMSQTNSG NIMMQRSNFK GPRRIVKCFN CGKEGHIARN 
421 DCTERQANFL GKIWPSHKGR PGNFLQNRPE PTAPPAESFR 
481 LKSLFGSDPL SQ* 
THMgagC (442 aal 
Identical to HMgagC, but without the sequence shown in bold 
(corresponding to a 50 aa C-terrninal truncation). 









Identical to HMgagC and THMgagC respectively, but with ala2 replacing gly2. 
F.2 Amino acid sequences of C-terminal fusion sequences 
112 
Note: The six C-terminal fusion sequences are shown immediately following GKIWPSHKGR PG (THMgag-fusions) 
or LKSLFGSDPL SQ (HMgag-fusions). 
3'RT (113 aa) 
, ,EFKGGVYY DPSKDLIAEI QKQGDDQWTY QIYQEPFKNL KTGKYAKRRT THTNDVKQLT 
EAVQKISLES IVTWGKTPKF RLPIQKETWE IWWTDYWQAT WIPEWEFVNS GRFRI* 
PE (115 aa) 
.. EFPPIPVG EIYKRWIIFR DYVDRFYKTL RAIFQSSMTK ITLWQRPLVE RYLKDQQLLT 
VYYGVPVWKR PQVPLRPMTY KAVDLSHFLK EKGGLILKEP VHGVYHPDIV IYQYMDDLTP 
GPGVRYPLAC TPYDINQMLR GPGRAFVTIP NPLLGLD* 
3'TN (169 aa) 
.. EFKGALTS SNTAHNNPDC AWLQAQEEEE DVGFPVRPQV PLRPMTYKAA FDLSFFLKEK 
GGLEGLIHSK RRQDILDLWV YHTQGYFPDW QNYTPGPGVR YPLTFGWCFK LVPVDPREVE 











TN (322 aa) 
· . EFKGMVGI SYGRKKRRQR RSTPPSSEDH QNPISKQPLP QTRGDPTGSE ESKKKVESKT 
KTDPFDCKYC SYHCLVCFQT KGLGISYGRK KRMEPIDPNL EPWNHPGSQP NTPCNKCYCK 
YCSYHCLVVG WPAVRERIRR TEPAAEGVGP ASQDLDKHGA LTSSNTAHNN PDCAWLQAQE 
EEEDVGFPVR PQVPLRPMTY KAAFDLSFFL KEKGGLEGLI HSKRRQDILD LWVYHTQGYF 
PDWQNYTPGP GVRYPLTFGW CFKLVPVDPR EVEEANKGEN NCLLHPMSQH GMEDADREVL 
RWVFDSSLAR RHLAREKHPE YYKD* 
RT (450 aa) 
· .EFCGKKAI GTVLVGPTPV NIIGRNMLTQ LGCTLNFPIS PIETVPVKLK PGMDGPKVKQ 
WPLTEVKIKA LTAICEEMEK EGKITKIGPE NPYNTPIFAI KKEDSTKWRK LVDFRELNKR 
TQDFWEVQLG IPHPAGLKKK KSVTVLDVGD AYFSVPLDEG FRKYTAFTIP SINNETPGIR 
YQYNVLPQGW KGSPAIFQAS MTKILEPFRA KNPEIVIYQY MAALYVGSDL EIGQHRAKIE 
ELREHLLKWG FTTPDKKHQK EPPFLWMGYE LHPDKWTVQP IQLPEKDSWT VNDIQKLVGK 
LNWTSQIYPG I KVRQLCKLL RGTKALTDIV PLTEEAELEL AENREILKEP VHGVYYDPSK 
DLIAEIQKQG DDQWTYQIYQ EPFKNLKTGK YAKRRTTHTN DVKQLTEAVQ KISLESIVTW 
GKTPKFRLPI QKETWEIWWT DYWQATWIPE WEFVNSGRFR 1* 
RTTN (778 aa) 
· . EFCGKKAI GTVLVGPTPV NIIGRNMLTQ LGCTLNFPIS PIETVPVKLK PGMDGPKVKQ 
WPLTEVKIKA LTAICEEMEK EGKITKIGPE NPYNTPIFAI KKEDSTKWRK LVDFRELNKR 
TQDFWEVQLG IPHPAGLKKK KSVTVLDVGD AYFSVPLDEG FRKYTAFTIP SINNETPGIR 
YQYNVLPQGW KGSPAIFQAS MTKILEPFRA KNPEIVIYQY MAALYVGSDL EIGQHRAKIE RT 
ELREHLLKWG FTTPDKKHQK EPPFLWMGYE LHPDKWTVQP IQLPEKDSWT VNDIQKLVGK 
LNWTSQIYPG I KVRQLCKLL RGTKALTDIV PLTEEAELEL AENREILKEP VHGVYYDPSK 
DLIAEIQKQG DDQWTYQIYQ EPFKNLKTGK YAKRRTTHTN DVKQLTEAVQ KISLESIVTW 
GKTPKFRLPI QKETWEIWWT DYWQATWIPE WEFVNSGRKL ATMVG 
ISYGR KKRRQRRSTP Shuffled 
PSSEDHQNPI SKQPLPQTRG DPTGSEESKK KVESKTKTDP FDCKYCSYHC LVCFQTKGLG Tat 
ISYGRKKRME PIDPNLEPWN HPGSQPNTPC NKCYCKYCSY HCLV 
VGWPAV RERIRRTEPA 
AEGVGPASQD LDKHGALTSS NTAHNNPDCA WLQAQEEEED VGFPVRPQVP LRPMTYKAAF 
Nef 
DLSFFLKEKG GLEGLIHSKR RQDILDLWVY HTQGYFPDWQ NYTPGPGVRY PLTFGWCFKL 
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